

PASPCR

June 2002
Vol. 10 Number 2

Newsletter



Introduction... by Bill Oetting

The PanAmerican Society for Pigment Cell Research has two major sources of information about our society, the *PASPCR Newsletter*, and the *PASPCR Web Site*. The internet presence of the PASPCR began as a Gopher site in February 28, 1994 (the PASPCR Gopher site still exists), and was administered by DeWayne Townsend, at the University of Minnesota. Vince Hearing created the first PASPCR Web Site in early 1995, and later that year the site was moved to the same server that contained the PASPCR Gopher site. Since then, the PASPCR Web Site has undergone numerous alterations. At present, the web site receives over 16 'hits' per day, and has accumulated over 30,000 visits since 1996. This number does not include multiple hits from the same IP address, but represents different individuals who are visiting the PASPCR Web Site.

The PASPCR Web Site is the major, up-to-date source of current information for the PASPCR membership and for individuals who are interested in the PASPCR. The PASPCR Web site is not only includes new information, but it is also a repository on the history of our society, our goals and our by-laws. This site also includes a registration page for potential new members and I have received well over 30 requests over the last two years. This is a very cost effective means to disseminate information about the PASPCR. If there is additional information that you would like to see on the Web site, or you would like to include information of past PASPCR activities, please let me know and I will add them. A visit to our web site may be the first time that an individual has heard about the PASPCR, and we should present ourselves in the best possible light. I look forward to your comments and inclusions.

The PASPCR Web Site can be found at:

<http://www.paspcr.org>

The *PASPCR Newsletter* is published quarterly and is intended to serve as a means of communication for the members of our Society. You are invited to contribute articles, or other information you feel will be of interest to members of the PASPCR. If you attend a scientific meeting and have heard results which you think will be of interest to the membership of the PASPCR, please write a few paragraphs summarizing what was presented and share it with us. Any information on upcoming meetings of interest will be added to the "Calendar of Events". We also want to note any change of affiliation or address that you may have had to help us keep our membership list up-to-date. This is your Newsletter, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to me, preferably by E-mail, to bill@lenti.med.umn.edu.

Due to problems with the domain names obtained for the IFPCS, the addresses IFPCS.info and IPCC.info are currently not active. I am trying to get these addresses back, but there is a possibility that they will be lost. I will let you know the results when they become available.

In this Issue

PASPCR Officers.....	2
Calendar of Events.....	2
Corporate Sponsors.....	3
Some Items of Interest.....	3
Model Organisms (Medaka).....	4
Mouse News.....	4
Positions Wanted/Available.....	5
And now for the rest of the story.....	6
2002 IPCC Program.....	7
Melanoma Research News.....	11
Melanoma Research Congress	
Bibliography.....	13

**The PanAmerican Society for
Pigment Cell Research**

C/O Dr. Raymond E. Boissy
Department of Dermatology
University of Cincinnati
231 Bethesda Avenue
Cincinnati, OH 45267-0592

Officers:

Zalfa Abdel-Malek,
President

John Pawelek
President-elect

Raymond E. Boissy
Secretary/Treasurer

Council Members:

Mary K. Cullen
Bryan Fuller
Ruth Halaban
Thomas J. Hornyak
Randy Morrison
Brian Potterf
Glynis Scott
Miri Seiberg
Vijay Setaluri

IFPCS Representative:

Richard A. King

Calendar of Events:

July 14-19, 2002 XIXth IUPAC Conference on Photochemistry will be held in Budapest.
Contact: The Hungarian Chemical Society, (MKE),
Fu u. 68. Hungary, H-1027 Budapest,
Phone: 36-1-201-6886
Fax: 36-1-201-8056
E-Mail: mail.mke@mtesz.hu.

Sept. 9 - 13, 2002 The XVIIIth International Pigment Cell Conference, to be held in The Hague, Holland.
Contact: Dr. Stan Pavel, President ESPCR,
University Hospital Leiden, Dept of Dermatology,
PO Box 9600, NL - 2300 RC LEIDEN
Phone: 31-(71) 526 1952
Fax: 31-(71) 524 8106;
E-mail: SPavel@algemeen.azl.nl
Website: <http://www.ipcc.info>

Dec. 14-18, 2002 The American Society for Cell Biology 42nd Annual Meeting is to be held in San Francisco, CA
For more information: www.ascb.org

Sept. 3-7, 2003 XIth Annual Meeting of the PanAmerican Society for Pigment Cell Research, to be held in Wood's Hole, MA.
Contact: Dr. Jean Bolognia.
E-mail: jean_bolognia@qm.yale.edu.

Sept. 17-20, 2003 XIth Annual Meeting of the European Society for Pigment Cell Research, to be held in Gent.
Contact: Prof. JeanMarie Naeyaert.
E-mail: JeanMarie.Naeyaert@rug.ac.be.

The *PASPCR Newsletter* is published quarterly by the PanAmerican Society for Pigment Cell Research. All views are those of the authors. For further information or to submit articles, please contact members of the Publications Committee.

Publications Committee:

William S. Oetting, Ph.D.
Editor

University of Minnesota
Department of Medicine- Genetics
MMC 485
420 Delaware St. SE
(612) 624-1139
bill@lenti.med.umn.edu

Vijayasardhi, Setaluri, Ph.D.

Wake Forest University School of Medicine
Department of Medicine
Winston-Salem, NC 27157
(336) 716-3273
setaluri@bgsu.edu

Giselle Thibaudeau, Ph.D.

Mississippi State University
Department of Biological Sciences
Harned Hall
Mississippi State, MS 39762
(662) 325-7572
giselle@ra.msstate.edu

Corporate Sponsors *by Raymond E. Boissy*

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

GOLD Corporate Patrons

Procter and Gamble Co.
Shiseido Co, Ltd.

SILVER Corporate Patrons

Avon Products, Inc.
Galderma Laboratories, Inc
Stiefel Laboratories
Combe, Inc.

Some Items of Interest:

The American Society for Cell Biology 42nd Annual Meeting is in San Francisco, December 14-18, 2002. Full details about the meeting are on the ASCB website www.ascb.org. If you would like to receive a copy of the Call for Abstracts send an e-mail to ascbinfo@ascb.org The Abstract deadline is August 1. The meeting opens on Saturday afternoon, December 14 with Special Interest Subgroups. The opening Reception is Saturday Evening at 6:00 PM and is titled, "Opportunities & Challenges in Cell Biology". The Chairs are Steven M. Block, R. Alta Charo, Ron McKay, and Andrew W. Murray. Sunday, December 15-Wednesday December 18 there will be two morning Symposia, and each afternoon will be your choice of 8 Minisymposia. Over 3,000 Poster Sessions will be presented. The Exhibit Hall will feature products and services for use by Cell Biologists. Over 350 companies will be Exhibiting. If you are looking for a job, or

have a job to fill, there will be a career center located next to the Exhibit Hall. Advanced Registration ends October 1. Minorities travel Award applications and Predoctoral travel Award Applications must be received by August 1.

From Miri Seiberg

Johnson & Johnson Skin Research Center training grant program

The Skin Research Center of the Johnson & Johnson Consumer Companies, Inc. investigates the molecular, cellular and physiological mechanisms involved in skin homeostasis and diseases. The Skin Research Center is committed to enhancing global scientific interactions and collaborations in the area of skin research and to enabling young scientists to become a part of the skin research community.

The Johnson & Johnson SRC training grant program supports postdoctoral training of basic research in skin biology or physiology in key universities, colleges and research institutions around the world. A key component of the Johnson & Johnson SRC training grant is the promotion of mutually beneficial relationships between Johnson & Johnson SRC scientists, grant recipients and their laboratories. The SRC training grant program seeks new scientific developments that could, over time, prove beneficial to Johnson & Johnson. More information on this program could be found at the PASPCR Web site: www.paspcr.org/P&Pskingrant.pdf.

From Lynn Lamoreux

We will discontinue the following stocks at the end of June. Anyone who wants these stocks should contact Lynn Lamoreux. All are congenic with C57BL/6J

Belted

Silver with black (this is not available elsewhere on B6)

Silver with brown

Slaty with chinchilla

Slaty with brown

Chinchilla with brown

Model Organisms

by Lynn Lamoreux

メダカ

(Medaka)

The Japanese medaka is a vertebrate research model that offers particular advantages to pigment cell research. This hardy little fish produces a dozen or more eggs at a predictable time each day, and it retains them attached to the female for several hours. Medaka is easy and inexpensive to raise and to transport; thus is suitable for research projects at all levels from the classroom to the sophisticated research laboratory. The domesticated fish models, of course, avoid problems faced in working with mammals or species that must be collected in the wild. At the same time, medaka uniquely satisfies some specific needs for biological research. For example, the See-Through Medaka is essentially transparent throughout its lifetime because it lacks most differentiated pigment cells. Thus, the See-Through Medaka is a unique and convenient organism for any research that will benefit from continual observation of a living vertebrate at all levels of organization from the whole organism to fluorescent-tagged cells/molecules.

The See-Through Medaka was created by Mendelian genetics, using mutations that prevent normal function of the four different types of medaka chromatophores. The mutations used to make the see-through medaka are available in all combinations. Thus the embryonic and adult development of the four types of melanophores can be observed in presence or absence of differentiated representatives of any or all of the other melanophore types. The rich resources of medaka mutants, combined with data obtainable from other species, especially zebra fish and mouse, offer information not otherwise readily available regarding the chromatophore lineage.

For more information on the Medaka fish and different mutants that are available, visit The Medaka Homepage at <http://biol1.bio.nagoya-u.ac.jp/>

Mouse News

by Lynn Lamoreux

Congenic inbred mice are important to evaluation of gene functions and genic interactions because the functions and interactions can be evaluated in absence of confounding changes in the background genome. However, the exclusive use of C57BL/6J congenics would eventually lead us to an unnaturally narrow view of the range of variability that can be expressed as a result of change in a given gene. Furthermore, genes to not function in isolation, and the expression of a gene against one inbred background will not tell us the rest of the story regarding its relationship with the genome as a whole. One method of evaluating the influence of background genome upon a specific gene function or genic interaction is place the same specific gene(s) in a contrasting genetic background.

One such opportunity exists when white-spotting genotypes are compared on JU/CtLm and C57BL/6J. Differences become apparent. Dr. Tomohisa Hirobe has reported differences in skin pigmentation when standard genes that affect melanogenesis are placed on a C57BL/10 background. For readers who are interested in using JU, please contact Lynn Lamoreux or check out the stocks maintained at the Wellcome Trust Functional Genomics Mouse Pigmentary Mutants Repository. <http://www.sghms.ac.uk/depts/anatomy/pages/WTFGMPMR.htm>

Dr. Hirobe's stocks are listed below.

C57BL/10JHir (black)
 C57BL/10JHir-A/A (agouti)
 C57BL/10JHir-b/b (brown) Tyrp1 locus
 C57BL/10JHir-c/c (albino) Tyr locus
 C57BL/10JHir-d/d (dilute)
 C57BL/10JHir-p/p (pink-eyed dilution)
 C57BL/10JHir-Wsh/Wsh (sash) Kit locus
 C57BL/10JHir-e/e (recessive yellow) Mc1r locus
 C57BL/10JHir-slt/slt (slaty)
 C3H/HeJ/msHir

Tomohisa Hirobe, Ph. D.
 Team Leader
 Radiation Hazards Research Group
 National Institute of Radiological Sciences
 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan
 Tel: +81-43-206-3253 or 3133
 Fax: +81-43-206-3139
 E-mail: thirobe@nirs.go.jp

Keep the membership informed.

If you have news about a member of the PASPCR, please let us know. Contact a member of the publications committee and we will make sure that it is in the next issue.

Positions - Wanted and Available

Postings for **Positions Available** will be open to all individuals and institutions so long as the position is related to pigment cell research. Postings for **Positions Wanted** will be open only to members of the PanAmerican Society for Pigment Cell Research or its sister societies (JSPCR and ESPCR). Send postings to Bill Oetting at bill@lenti.med.umn.edu. Please provide an expiration date for any submitted postings. Final decisions will be made by the Publications Committee of the PASPCR.

Postdoctoral Position

Polarized Kit-ligand expression in the epidermis: Its role in human melanocyte homeostasis

A postdoctoral position (fully funded for the first year with the possibility of a 2 year extension) is immediately available in the Department of Pathology, Centre Medical Universitaire at the University of Geneva, Switzerland. The project is supervised by Dr. Bernhard Wehrle-Haller and Prof. Beat Imhof and is within the frame of a collaboration between the University of Geneva and Industry.

The aim of this project is to understand the role of kit-ligand in melanocyte homeostasis in the adult epidermis and how manipulation of kit-ligand expression or localization in keratinocytes affect melanocyte behavior. The project will employ cell-biological, pharmaceutical, biochemical as well transgenic approaches (mouse) to develop methods to modify Kit-ligand localization (polarity and cell surface expression) in vivo and to study melanocyte behavior in response to such altered Kit-ligand presentation. For references and rational see Wehrle-Haller and Imhof (2001, J. Biol. Chem. 276, 12667-74) and Grichnik et al., (1998, J. Invest. Dermatol. 111, 233-38).

The Centre Medical Universitaire provides a stimulatory research environment located within the City of Geneva. Research in the department is centered around problems of autoimmunity, wound healing, inflammation, cell-cell junctions and cell migration. Geneva, located at the lake of Geneva in close proximity to the French Alps, provides a rich multicultural environment facilitating social integration.

Interested candidates preferably having experience in one or more of the aforementioned domains should send their CV (e.g. e-mail) including names and contacting information of two references to:

Bernhard Wehrle-Haller PhD
Department of Pathology
Centre Medical Universitaire
1. Rue Michel-Servet
1211 Geneva 4
Switzerland
Tel/Fax: 0041 22 702 5735 / 5746
Bernhard.Wehrle
Haller@medecine.unige.ch

Postdoctoral Research Position

A postdoctoral position is available immediately to study the transcriptional co-repressor and co-activator activities of the oncogenic protein Ski in human melanomas (PNAS (USA) 97:5924-5929, 2000). Seeking individuals with experience in EMSA, *in vitro* transcription-translation, site-directed mutagenesis and yeast two-hybrid screening. Interested individuals should send inquiries and applications (including CV, a brief description of past experience and future research interests, and the name of three references) to:

Estela E. Medrano, Ph.D.
Huffington Center on Aging
Baylor College of Medicine
One Baylor Plaza N-803.01
Houston, TX 77030

Baylor College of Medicine is an Equal Opportunity Employer

Research Associate/Post Doctoral Fellow Position Available

Position available for either an entry level postdoctoral fellow or a more senior research associate to study the molecular and cellular biology

of the melanocyte in general and the pathophysiology of vitiligo in specific. The research project will focus globally on the role of survival factors and apoptotic regulators on the viability of melanocytes in the skin and in culture. In addition, the project will focus on the genetic and cellular susceptibility of melanocytes from patients with vitiligo to under apoptosis in response to various stimuli. Postdoctoral fellow candidate should have experience with routine molecular and cellular techniques including cell culturing, site directed mutagenesis, and protein biochemistry. Research Associate candidate should have similar experiences utilizing the melanocyte system. Candidate will become part of an interactive research group focusing of various aspects of pigmentation in the Department of Dermatology and on skin physiology in the Skin Sciences Institute within the University of Cincinnati College of Medicine. Send curriculum vitae and list of three references to:

Raymond E. Boissy, Ph.D.
Professor of Dermatology and Cell Biology,
Neurobiology, & Anatomy
Department of Dermatology
University of Cincinnati College of Medicine
231 Albert Sabin Way, ML-0592
Cincinnati, OH, 45267-0592
TEL: 513-558-6242
FAX: 513-558-0198
E-mail: boissyre@email.uc.edu

Principal Scientist- Clinical Research - Skin Science Research

Unilever employs over 200 scientists at our New Jersey Laboratory who are dedicated to innovative and scientifically rigorous skin research programs. Our world sales exceed \$40 billion so our programs have solid financial funding allowing for an innovative and challenging research culture. We currently have a full time opening that provides a unique opportunity to apply your basic science skills to human studies that impact the condition of skin for hundreds of millions people worldwide. We are seeking an expert in pigment biology or photobiology who can advance our knowledge and link laboratory research to clinically defined improvements of consumer skin problems. As a member of our skin research team, you will have an opportunity to work with other scientific experts in many fields including cell biology, biochemistry, measurement science and physical chemistry. You will also be encouraged to establish

and maintain close ties to research in academic and government research communities.

We offer a competitive salary, benefits including tuition assistance and relocation, and a dynamic environment filled with learning and discovery beyond conventional scientific boundaries. Applicants must be authorized to work in the USA. For consideration please forward your CV to: Human Resources, Dept. CR-SID, Unilever Research US, 45 River Road, Edgewater, NJ 07020 or E-Mail: job.mca@unilever.com . Please place only the letters "CR-SID" as the subject of your e-mail. Unilever is an Equal Opportunity Employer m/f/d/v.

Postdoctoral Fellows - Cancer and Developmental Biology - Two NIH-funded positions are available for fellows interested in studying the Hedgehog signaling pathway in development and disease using skin as a model system. One project centers on defining the function of the Hedgehog pathway during skin appendage morphogenesis (*Dev. Biol.* 205: 1-9, 1999); a second project focuses on understanding how deregulated activation of this pathway gives rise to basal cell carcinomas (*Nature Genet.* 24: 216-7, 2000). Applicants should have a solid background in molecular and cell biology, with experience in transgenic animal models desirable but not required. Interested individuals should send a CV, letter of interest, and names of three references to: Dr. Andrzej Dlugosz, University of Michigan, Department of Dermatology and Comprehensive Cancer Center, 3310 CCGC, Box 0932, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0932 Email: dlugosza@umich.edu. The University of Michigan is an Equal Opportunity Employer.

And now for the rest of the story.

There is no story for this issue. Please look in the September issue for the next installment.

If you wish to know how a particular line of investigation got started, or know of a story that would be interesting to readers of the PASPCR Newsletter, please email me at bill@lenti.med.umn.edu, and I will try to get **the rest of the story**.

2002 IFPCS Conference

The XVIII th IPCC will take place at the Hotel Zuiderduin in Egmond aan Zee. Hotel Zuiderduin is situated in the dunes of Egmond aan Zee, one hundred meters from the North Sea. This beautiful, modern hotel is provided with a pub, swimming pool, sauna, beauty centre and fitness centre. Egmond aan Zee is a small fishermen town, with a lot of tourist attractions. Most prominent is the Jan van Speyck lighthouse.

Near Egmond aan Zee, the larger city of Alkmaar is found. Alkmaar is a medieval town which is still visible via the old town centre with a labyrinth of small streets. The most prominent buildings in town are The Great St. Laurens Church and the Weigh house. On Friday morning till half September there is a cheese market (for almost 400 years now) around the Weigh house.

SOCIAL PROGRAM

Welcome Reception

Sunday 8th September 2002, 17:00 - 19:00

Delegates and their accompanying persons are invited to attend this reception, which will take place in Hotel Zuiderduin

Boat Trip and Banquet in Grand Hotel Krasnapolsky, Amsterdam

Wednesday 11th September 2002, 16:30 - 23:30

The participants will have the opportunity to take part in an excursion to Amsterdam, where they will be taken on a boat tour through the canals. The Conference Banquet will take place at the Golden Tulip Grand Hotel Krasnapolsky.

The Golden Tulip Grand Hotel Krasnapolsky is situated directly opposite the Royal Palace on the Dam right in the heart of Amsterdam. The breathtaking Winter Garden, the glass palace dating from 1879, where the dinner will take place, is listed as National Monument.

Please note that the capacity in the Winter Garden is limited; tickets will be available on a first come, first served basis. (Dress code: informal)

Farewell Party

Thursday 12th September 2002, 19:00 - 23:00

Delegates and their accompanying persons are invited to attend the farewell party, which will take place in Hotel Zuiderduin.

Active Jazz players: a dixieland band from the medical faculty from Prague will entertain us during the farewell party and a jam-session will be organized. Take your instrument with you !!!

The following is the scientific program for The XVIIIth International Pigment Cell Conference, to be held in The Hague, Holland. For the most current information, go to the IPCC web site at <http://users.raketnet.nl/ipcc/>

SCIENTIFIC PROGRAM

Sunday 8th September 2002

Council Meetings

Building up exhibitions

Poster mounting

14:30 - 17:00 *Registration*

17:00 - 19:00 *Welcome Reception*

Monday 9th September 2002

Morning:

Welcome and Opening Remarks

Special Lecture: Videomicroscopy in Pigment Cell Research (P. Friedl, Germany)

Plenary Symposium: Biochemistry and Molecular Biology of Melanogenesis

Special Lecture: What is wrong in xeroderma pigmentosum

(J.H.J. Hoeijmakers, The Netherlands)

Plenary Symposium: Photochemistry and Skin Pigmentation

Lunch and poster viewing

Afternoon:

Plenary Symposium: Epidemiology of Melanoma and Precursor Lesions

Press Conference: Nevi and UV radiation as risk factors for melanoma

Evening:

Concurrent workshops

Workshop I: Immunobiology of Melanocytes and Melanoma.

Workshop II: Melanocyte Microscopy; Imaging and Ultrastructural Studies

Dinner at Hotel Zuiderduin

Tuesday 10th September 2002Morning:

Plenary Symposium IV: Genetics of Pigmentation

Special Lecture: Molecular genetics of pigmentary disorders (R.A. Spritz, U.S.A.)

Seiji Memorial Lecture

Lunch and Poster viewing / Women forum

Afternoon:

Plenary Symposium: Developmental Biology of Pigmentary System

Concurrent Workshops

Workshop I: Chemistry of Eumelanin and Pheomelanin

Workshop II: Comparative Biology; Other Pigmentary Systems

Dinner at Hotel Zuiderduin

Wednesday 11th September 2002Morning:

Presidential Address: Melanin and melanogenesis: a fascinating target for chemists (S. Ito, Japan)

Plenary Symposium: Cutaneous and Ocular Melanoma: Genetics and Basic Biology

Concurrent workshops

Workshop I: Extracutaneous Pigmentation

Workshop II: (Patho)physiological Aspects of Melanosomes

Lunch and poster viewing

Afternoon:

Special lecture: The role of melanocortin-1-receptor polymorphism in skin cancer risk (R.A. Sturm, Australia).

Plenary Symposium: Cell Biology and Cell Signalling in Melanocytes

Excursion to Amsterdam, Boat Trip and Banquet, 16:30 - 23:30

Banquet at Hotel Krasnapolsky, Amsterdam

Thursday 12th September 2002Morning:

Plenary Symposium: Cutaneous and Ocular Melanoma: Diagnosis and Treatments

Plenary Symposium: Vitiligo and Other Pigmentary Disturbances

Lunch and poster viewing

Afternoon:

Plenary Symposium: Hot Topics

Special lecture: Identification of Melanocyte and Melanoma Biomarkers using

DermArray DNA Microarrays (T.P. Dooley, U.S.A.)

Plenary Symposium: Genomics and Proteomics in Pigment Cell Research

Closing remarks

19:00-23:00 Farewell Party (Hotel Zuiderduin)

Note:

The following persons have been invited to present their recent work in the above mentioned plenary symposia:

Z. Abdel-Malek (U.S.A.); R. Balloti (France); J. Bologna (U.S.A.); L. Brochez (Belgium); A.M. Eggermont (The Netherlands); Garcia-Borron (Spain); V.J. Hearing (U.S.A.); M. Herlyn (U.S.A.); Imokawa, G. (Japan), R. MacKie (U.K.); S. Shibahara (Japan); K. Toyofuku (Japan).

Friday 13th September 2002**SATELLITE SYMPOSIA****I. The Congenital Giant Naevus: Research and Treatment**

Organiser: H. Etchevers (France).

The symposium may be of particular interest for dermatologists, plastic and reconstructive surgeons and scientists involved in the molecular and cell biology of congenital (giant) naevi. Sessions of grouped short presentations will be followed by round table exchanges with the audience. Presentation abstracts and lunch will be provided. The following topics are anticipated:

dermabrasion, dermal and epidermal substitutes, epidemiology, fetal naevogenesis, malignant transformation, neurocutaneous melanosis, phototherapy, scarring in and near naevi, satellite naevi, skin mobilisation, targeted immunotherapy, the naevocyte in vitro, tissue expanders. The first Annual Meeting of Naevus 2000 France-Europe's Committee on Medicine and Science will follow the symposium.

For more information regarding the scientific program, please contact:

IPCC Naevus Symposium
c/o Dr. Heather Etchevers
Institut d'Embryologie Cellulaire et Moléculaire
49bis avenue de la Belle Gabrielle
F-94736 Nogent-sur-Marne Cedex, France
Phone: +33-1 45 14 15 11, Fax: +33-1 48 73 43 77
E-mail: etchever@infobiogen.fr

II. Melanoma Biology

Organisers: D. J. Ruiter (The Netherlands), G.N.P. van Muijen (The Netherlands), M. Herlyn (U.S.A.)

The aim of the satellite symposium is to discuss new concepts in melanoma biology, new techniques that enable further observation in animal and human tumors, new approaches for diagnostic and prognostic purposes, and new strategies for immunologic therapy. The symposium will consist of invited lectures that will be divided in four successive sessions. Presentations will be given by leading experts in the field. The meeting will take place from 9:00 until 17:30 and will be followed by cocktails and dinner. Coffee / tea and lunch will also be provided.

A tentative program with the speakers who have been invited is given bellow:

New Concepts:

Stem cells and stromagenesis; (M. Herlyn; Philadelphia)

Lymphangiogenesis (R. de Waal; Nijmegen)

Dynamics of tumor invasion (P. Friedl, Wuerzburg)

New Technologies:

Transgenic mouse model (P. Krimpenfort; Amsterdam)

Spectral imaging of transcription factor expression (D. Becker; Pittsburg)

Tetramere staining of cytotoxic lymphocytes (M. Bernsen; Nijmegen)

New Approaches in Diagnosis and Prognosis:

Comparative genomic hybridization-based microarrays (B. Bastian; San Francisco)

Cytokine profiles (D. Schadendorf; Mannheim)

Uveal melanoma as a paradigm (M. Jager; Leiden)

New Strategies for Immunologic Therapy:

Melanosomal proteins (V.Hearing; Bethesda)

Dendritic cells (G. Adema; Nijmegen)

New targets (M.Bar-Eli; Houston)

For more information regarding the scientific program, please contact

Prof. Dr. D. J. Ruiter
Department of Pathology
University Medical Center St Radboud
P.O.Box 9101
NL-6500 HB Nijmegen
The Netherlands
Phone: +31-24-3614825; Fax:+31-24-3540520
E-Mail: d.ruiter@pathol.azn.nl

III. Pigment Cell Societies Development Group

Organiser: Dr. W. Pavan

The International Federation of Pigment Cell Societies Development Group is hosting a one-day satellite meeting designed to coalesce the remarkable recent progress in the field of pigment cell development with research aimed at gaining new insights into differentiation, gene expression and embryology. This meeting will explore these themes by gathering experts in a broad range of fields spanning basic transcriptional mechanisms through the clinical impact of pigment cell research. The program will include talks from invited group members and talks selected from abstract submissions. Our goal is to bring together a diverse group of dynamic speakers and participants who can together explore the current findings in pigment cell development.

For more information contact:

William J. Pavan, Ph.D.
Genetic Disease Research Branch
Building: 49, Room 4A82
National Institutes of Health
National Human Genome Research Institute
49 Convent Drive MSC4472
Bethesda, Maryland 20892, U.S.A.
Phone (301) 402-2036; 496-7584
Fax (301) 402-2170
E-mail: bpavan@nhgri.nih.gov
http://www.nhgri.nih.gov/Pigment_Cell/

IV. Hyperpigmentation and hypopigmenting agents

Co-chair James J. Nordlund (PASPCR), Jean-Paul Ortonne (ESPCR) and Masako Mizoguchi (JSPCR)

1. Introduction: The problem of hyperpigmentation -J Nordlund (USA)

2. Melasma and hyperpigmentation: histological studies- Won Hyoung Kang, Ajou (Korea)

3. New studies on the causes of melasma; role of contact and photodermatitis in melasma- Vermeulen Verallo-Rowell Manila, Philippines

4. Dermal melanosis and melanocytosis: current therapies in the Far East- Masako Mizoguchi, Japan

5. Review of therapies in Europe and results with lightening agents for treatment of pigmentary problems- Wiete Westerhof (The Netherlands)

6. Review of new therapies in US and work on, anisole and combination therapies- Jean Bologna (USA)

Coffee break

7. Review of treatment of hyperpigmentation in South America- Doris Hexsel

8. Review of arbutin and derivatives- Ray Boissy (USA)

9. Theoretical Approches to hypopigmenting skin- a basis in cell biology- Matsumitsu Ichihashi (Japan)

10. Theoretical Approches to hyperpigmenting skin- a basis in cell biology- Jean Paul Ortonne (France)

11. Metabolism of melanosomes: Is melanin biodegradable? -Jan Borovansky (Czech Republic)

12. Open Discussion



This is a tentative agenda for the first Annual Melanoma Research Congress. It does not contain names but the work shops etc. Please contact Meenhard or DuPont Guerry for more information.

First Annual Melanoma Research Congress

June 21-24, 2003

Wyndham Franklin Plaza Hotel
17th & Race Streets
Philadelphia, PA 19103
(Phone: 215-448-2852; Fax: 215-448-2853)

Sponsored by the Foundation for Melanoma Research and Other Foundations

Conference Co-Chairs

Meenhard Herlyn The Wistar Institute Philadelphia, PA	DuPont Guerry University of Pennsylvania Philadelphia, PA
---	---

Saturday, June 21

3:00 pm to 10:00 pm **REGISTRATION**

7:00 pm to 9:00 pm **Keynote Addresses**

Steven Rosenberg
Rational Immunotherapy of Melanoma

Jeff Trent
Genomics approaches to Melanoma Biology

9:00 pm to 10:00 pm **OPENING RECEPTION**

Sunday, June 22

8:00 am to 10:30 am **Plenary Session 1**

Immunobiology and Immunotherapy of Melanoma

Giorgio Parmiani, Chair

Drew Pardoll
Thierry Boon
Soldano Ferrone
Ralph Reisfeld

10:30 am to 11:00 am **Break**

11:00 am to 12:30 pm **Workshops 1-3**

Workshop 1

Experimental Melanocyte Transformation

Scott Lowe
Carola Berking
Marisol Soengas
Glenn Merlino

Workshop 2

Genetics of Familial Melanoma

Alisa Goldstein
David Hoog
Nick Hayward
Julia Newton Bishop

Workshop 3

Melanocyte Development and Melanoma

David Fisher
Heinz Arnheiter
Bill Pavan
Nishimura?

12:30 pm to 2:00 pm **Break**

2:00 pm to 4:00 pm **Plenary Session 2**

Molecular Epidemiology of Melanoma

Marianne Berwick, Chair

Margarete Tucker
Tim Rebbeck
Mann/Kefford/
Landis/Bergman

4:00 pm to 4:30 pm **Break**

4:30 pm to 6:00 pm **Workshops 4-6**

Workshop 4

Immunobiology II

Susan Topalian
Franco Marincola
Ingegerd Hellstroem
Walter Storkus

Workshop 5

UV and Melanoma

Glenn Merlino
Vince Hearing
Rick Sturm
Frances Noonan
Ed DeFabo

Workshop 6
Molecular and Functional Genomics of Melanoma
David Speicher
Katheryn Resing
Boris Bastian

8:00 pm to 10:00 pm **Poster Session 1**
Immunobiology and Immunotherapy of Melanoma

Monday, June 23

8:00 am to 10:00 am **Plenary Session 3**
Biology of Melanoma
Dorothea Becker, Chair
Meenhard Herlyn
Ze'ev Ronai
Ruth Halaban
Lynda Chin

10:00 am to 10:30 am **Break**

11:00 am to 12:30 pm **Workshops 7-9**
Workshop 7
Biomarkers
David Hoon
Anja Bosserhoff
Dirk Ruitter
DuPont Guerry

Workshop 8
Tumor Progression
David Elder
Martin Mym
Alistar Cochran

Workshop 9
Bioinformatics for Genomics and Proteomics
Todd Golub
Towia Liebermann
Phyllis Gimotty
Louise Showe

12:30 pm to 2:00 pm **Break**

2:00 pm to 4:00 pm **Plenary Session 5**
Invasion and Metastasis of Melanoma
I. Fidler
D. Ruitter
R. Muschel
D. Welsh

4:00 pm to 4:30 pm **Break**

4:30 pm to 6:30 pm **Poster Session B**
Etiology, Biology, Prevention, and
Novel Therapy of Melanoma

Advocates and Melanoma Research
DuPont Guerry

8:00 pm to 10:00 pm **Reception/Dinner**
Inauguration of the
Society for Melanoma Research
Advocate Speaker

Tuesday, June 24

8:00 am to 10:00 am **Plenary Session 6**
Novel Concepts for Melanoma Etiology,
Prevention, Diagnosis, and Prognosis
Meenhard Herlyn
Robert Benezra/Raffi
Mary Hendrix
Catherine Verfaillie

10:00 am to 10:30 am **Break**

10:30 am to 12:30 am **Plenary Session 7**
Hot Topics in Non-immunological Therapy of
Melanoma
Bob Wittes
Disease Gene Identification
Genomics of Drug Discovery

Bibliography:

The Bibliography published in this issue covers the period March, 2002 through May, 2002. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. By its very nature, assignment of a reference to a particular category is arbitrary and we urge you to read through all categories to make sure you don't miss any pertinent to your field.

MELANINS, MELANOGENS & MELANOGENESIS

- Alaluf S, Atkins D, Barrett K, Blount M, Carter N, Heath A: Ethnic variation in melanin content and composition in photoexposed and photoprotected human skin. *PIGM CELL RES* 15:112-118 (2002).
- Alaluf S, Atkins D, Barrett K, Blount M, Carter N, Heath A: The impact of epidermal melanin on objective measurements of human skin colour. *PIGM CELL RES* 15:119-126 (2002).
- Aubry AF. Applications of affinity chromatography to the study of drug-melanin binding interactions. *J CHROMATOGR B* 768[1], 67-74. 2002.
- Banning TP, Heard CM: Binding of doxycycline to keratin, melanin and human epidermal tissue. *INT J PHARM* 235:219-227 (2002).
- Carzaniga R, Fiocco D, Bowyer P, O'Connell RJ: Localization of melanin in conidia of *Alternaria alternata* using phage display antibodies. *MOL PLANT MICROBE INTERACTION* 15:216-224 (2002).
- Choi SY, Kim S, Kim H, Suk K, Hwang JS, Lee BG, Kim AJ, Kim SY: (4-methoxy-benzylidene)-(3-methoxy-phenyl)-amine, a nitrogen analog of stilbene as a potent inhibitor of melanin production. *CHEM PHARM BULL TOKYO* 50:450-452 (2002).
- Croxatto A, Chalker VJ, Lauritz J, Jass J, Hardman A, Williams P, Cámara M, Milton DL: VanT, a homologue of *Vibrio harveyi* LuxR, regulates serine, metalloprotease, pigment, and biofilm production in *Vibrio anguillarum*. *J BACTERIOL* 184:1617-1629 (2002).
- Dwyer T, Blizzard L, Ashbolt R, Plumb J, Berwick M, Stankovich JM: Cutaneous melanin density of caucasians measured by spectrophotometry and risk of malignant melanoma, basal cell carcinoma, and squamous cell carcinoma of the skin. *AMER J EPIDEMIOLOG* 155:614-621 (2002).
- Hachiya A, Kobayashi T, Takema Y, Imokawa G: Biochemical characterization of endothelin-converting enzyme-1 α in cultured skin-derived cells and its postulated role in the stimulation of melanogenesis in human epidermis. *J BIOL CHEM* 277:5395-5403 (2002).
- Hamilton AJ, Gomez BL: Melanins in fungal pathogens. *J MED MICROBIOL* 51:189-191 (2002).
- Hayashi H, Fujii R: Possible involvement of nitric oxide in signaling pigment dispersion in teleostean melanophores. *ZOOL SCI* 18:1207-1215 (2001).
- Ikeda R, Sugita T, Jacobson ES, Shinoda T. Laccase and melanization in clinically important *Cryptococcus* species other than *Cryptococcus neoformans*. *J CLIN MICROBIOL* 40[4], 1214-1218. 2002.
- Jastrzebska M, Kocot A, Tajber L. Photoconductivity of synthetic dopa-melanin polymer. *J PHOTOCHEM PHOTOBIOLOG B BIOL* 66[3], 201-206. 2002.
- Katritzky AR, Akhmedov NG, Denisenko SN, Denisko OV: H-1 NMR spectroscopic characterization of solutions of Sepia melanin, Sepia melanin free acid and human hair melanin. *PIGM CELL RES* 15:93-97 (2002).
- Koo HM, VanBrocklin M, McWilliams MJ, Leppla SH, Duesbery NS, VandeWoude GF: Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. *PROC NATL ACAD SCI USA* 99:3052-3057 (2002).
- Kuhnen C, Herter P, Soimaru C, Homann HH, Johnen G: Pigmented (melanotic) neurofibroma. Report of an unusual case with immunohistochemical, ultrastructural and cytogenetic analyses. *PATHOL RES PRACT* 198:125-131 (2002).
- Mannerström M, Zorn-Kruppa M, Diehl H, Engelke M, Toimela T, Mäenpää H, Huhtala A, Uusitalo H, Salminen L, Pappas P, Marselos M, Mäntylä M, Mäntylä E, Tähti H: Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. *TOXICOL VITRO* 16:193-200 (2002).
- Mas JS, Martínez-Esparza M, Bastida CM, Solano F, Peñafiel R, García-Borrón JC: Regulation of ornithine decarboxylase in B16 mouse melanoma cells: synergistic activation of melanogenesis by α MSH and ornithine decarboxylase inhibition. *BBA MOL CELL RES* 1542:57-65 (2002).
- Nofsinger JB, Liu Y, Simon JD. Aggregation of eumelanin mitigates photogeneration of reactive oxygen species. *FREE RADICAL BIOL MED* 32[8], 720-730. 2002.
- Sowa MG, Matas A, Schattka BJ, Mantsch HH: Spectroscopic assessment of cutaneous hemodynamics in the presence of high epidermal melanin concentration. *CLIN CHIM ACTA* 317:203-212 (2002).
- Varas M, Pérez M, Ramírez O, DeBarioglio SR: Melanin concentrating hormone increase hippocampal synaptic transmission in the rat. *PEPTIDES* 23:151-155 (2002).

MELANOSOMES, MELANOCYTES & KERATINOCYTES

- Alaluf S, Heinrich U, Stahl W, Tronnier H, Wiseman S. Dietary carotenoids contribute to normal human skin color and UV photosensitivity. *J NUTR* 132[3], 399-403. 2002.
- Bahadoran P, Ortonne JP, Ballotti R: Melanosome trafficking? *M S MED SCI* 18:205-209 (2002).
- Barlow RJ, White CR, Swanson NA: Mohs' micrographic surgery using frozen sections alone may be unsuitable for detecting single atypical melanocytes at the margins of melanoma in situ. *BRIT J DERMATOL* 146:290-294 (2002).
- Barni S, Vaccarone R, Bertone V, Frascini A, Bernini F, Fenoglio C: Mechanisms of changes to the liver pigmentary component during the annual cycle (activity and hibernation) of *Rana esculenta* L. *J ANAT* 200:185-194 (2002).
- Bizario JCD, Nascimento AAD, Casaletti L, Patussi EV, Chociay MF, Larson RE, Espreafico EM: Expression of constructs of the neuronal isoform of myosin-Va interferes with the distribution of melanosomes and other vesicles in melanoma cells. *CELL MOTILITY CYTOSKEL* 51:57-75 (2002).
- Borodoker N, Cunningham ET, Yannuzzi LA, Nicoletti R: Peripheral curvilinear pigmentary streak in multifocal choroiditis. *ARCH OPHTHALMOL* 120:520-521 (2002).
- Brown RM, Darnton SJ, Papadaki L, Antonakopoulos GN, Newman J: A primary tumour of the oesophagus with both melanocytic and schwannian differentiation. Melanocytic schwannoma or malignant melanoma? *J CLIN PATHOL* 55:318-320 (2002).
- Cleaver JE, Crowley E. UV damage, DNA repair and skin carcinogenesis. *FRONT BIOSCI* 7, D1024-D1043. 2002.
- Curto EV, Lambert GW, Davis RL, Wilborn TW, Dooley TP. Biomarkers of human skin cells identified using DermArray DNA arrays and new bioinformatics methods. *BIOCHEM BIOPHYS RES COMMUN* 291[4], 1052-1064. 2002.
- Donatien P, Jeffery G: Correlation between rod photoreceptor numbers and levels of ocular pigmentation. *INVEST OPHTHALMOL VISUAL SCI* 43:1198-1203 (2002).
- Falcón-Pérez JM, Dell'Angelica EC: The pallidin (Pldn) gene and the role of SNARE proteins in melanosome biogenesis. *PIGM CELL RES* 15:82-86 (2002).
- Feng LJ, Novak EK, Hartnell LM, Bonifacino JS, Collinson LM, Swank RT: The Hermansky-Pudlak syndrome 1 (HPS1) and HPS2 genes independently contribute to the production and function of platelet dense granules, melanosomes, and lysosomes. *BLOOD* 99:1651-1658 (2002).
- Fukuda M, Kuroda TS, Mikoshiba K: Slac2-a/melanophilin, the missing link between Rab27 and myosin Va - Implications of a tripartite protein complex for melanosome transport. *J BIOL CHEM* 277:12432-12436 (2002).
- Goud B. How Rab proteins link motors to membranes. *NAT CELL BIOL* 4[4], E77-E78. 2002.
- Happle R: Speckled lentiginous nevus syndrome: Delineation of a new distinct neurocutaneous phenotype. *EUROPEAN J DERMATOLOGY* 12:133-135 (2002).
- Hemminki K, Xu GG, Kause L, Koulu LM, Zhao CY, Jansen CT. Demonstration of UV-dimers in human skin DNA in situ 3 weeks after exposure. *CARCINOGENESIS* 23[4], 605-609. 2002.
- Heys JJ, Barocas VH: Computational evaluation of the role of accommodation in pigmentary glaucoma. *INVEST OPHTHALMOL VISUAL SCI* 43:700-708 (2002).
- Hirobe T, Kawa Y, Mizoguchi M, Ito S, Wakamatsu K: Effects of genic substitution at the pink-eyed dilution locus on the proliferation and differentiation of mouse epidermal melanocytes in vivo and in vitro. *J EXP ZOOL* 292:351-366 (2002).
- Hirobe T, Wakamatsu K, Ito S, Abe H, Kawa Y, Mizoguchi M: Stimulation of the proliferation and differentiation of mouse pink-eyed dilution epidermal melanocytes by excess tyrosine in serum-free primary culture. *J CELL PHYSIOL* 191:162-172 (2002).
- Hume AN, Collinson LM, Hopkins CR, Strom M, Barral DC, Bossi G, Griffiths GM, Seabra MC: The leaden gene product is required with Rab27a to recruit myosin Va to melanosomes in melanocytes. *TRAFFIC* 3:193-202 (2002).
- Jean S, Bideau C, Bellon L, Halimi G, DeMéo M, Orsière T, Dumenil G, Bergé-Lefranc JL, Botta A: The expression of genes induced in melanocytes by exposure to 365-nm UVA: study by cDNA arrays and real-time quantitative RT-PCR. *BBA GENE STRUCT EXPRESS* 1522:89-96 (2001).
- Kahofer P, Hofmann-Wellenhof R, Smolle J: Tissue counter analysis of dermatoscopic images of melanocytic skin tumours: preliminary findings. *MELANOMA RES* 12:71-75 (2002).
- Kanetsky PA, Swoyer J, Panossian S, Holmes R, Guerry D, Rebbeck TR: A polymorphism in the agouti signaling protein gene is associated with human pigmentation. *AMER J HUM GENET* 70:770-775 (2002).
- Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H et al. Melasma: histopathological characteristics in 56 Korean patients. *BRIT J DERMATOL* 146[2], 228-237. 2002.
- Kawakami T, Soma Y, Kawa Y, Ito M, Yamasaki E, Watabe H, Hosaka E, Yajima K, Ohsumi K, Mizoguchi M: Transforming growth factor β 1 regulates melanocyte proliferation and differentiation in mouse neural crest cells via stem cell factor/KIT signaling. *J INVEST DERMATOL* 118:471-478 (2002).
- Kemp EH, Waterman EA, Hawes BE, O'Neill K, Gottumukkala RVS, Gawkrödger DJ, Weetman AP, Watson PF: The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. *J CLIN INVEST* 109:923-930 (2002).

- Khlestkina EK, Pestsova EG, Röder MS, Börner A: Molecular mapping, phenotypic expression and geographical distribution of genes determining anthocyanin pigmentation of coleoptiles in wheat (*Triticum aestivum* L.). *THEOR APPL GENET* 104:632-637 (2002).
- Kobayashi A, Hachiya A, Ohuchi A, Kitahara T, Takema Y: Inhibitory mechanism of an extract of *Althaea officinalis* L. on endothelin-1-induced melanocyte activation. *BIOL PHARM BULL* 25:229-234 (2002).
- Kuroda N, Hirano K, Inui Y, Yamasaki Y, Toi M, Nakayama H, Hiroi M, Enzan H: Compound melanocytic nevus arising in a mature cystic teratoma of the ovary. *PATHOL INT* 51:902-904 (2001).
- LePoole IC, Riker AI, Quevedo ME, Stennett LS, Wang E, Marincola FM, Kast WM, Robinson JK, Nickoloff BJ: Interferon- η reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. *AMER J PATHOL* 160:521-528 (2002).
- Loftus SK, Larson DM, Baxter LL, Antonellis A, Chen YD, Wu XF, Jiang Y, Bittner M, Hammer JA, Pavan WJ: Mutation of melanosome protein RAB38 in chocolate mice. *PROC NAT ACAD SCI USA* 99:4471-4476 (2002).
- Maitra A, Gazdar AF, Moore TO, Moore AY: Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: Laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi. *HUM PATHOL* 33:191-197 (2002).
- Marrero MD, Nagore E, Ramos-Níguez JA, Castejón P: Melanocytic agminated naevus on the sole. *BRIT J DERMATOL* 146:154 (2002).
- Miracco C, deSanti MM, Schürfeld K, Santopietro R, Lalinga AV, Fimiani M, Biagioli M, Brogi M, DeFelice C, Luzi P, Andreassi L: Quantitative in situ evaluation of telomeres in fluorescence in situ hybridization-processed sections of cutaneous melanocytic lesions and correlation with telomerase activity. *BRIT J DERMATOL* 146:399-408 (2002).
- Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, Fabbri P: New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions. *PIGM CELL RES* 15:87-92 (2002).
- Nagashima K, Torii S, Yi ZH, Igarashi M, Okamoto K, Takeuchi T et al. Melanophilin directly links Rab27a and myosin Va through its distinct coiled-coil regions. *FEBS LETT* 517[1-3], 233-238. 2002.
- Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, Moriyama M, Jackson IJ, Barrandon Y, Miyachi Y, Nishikawa S: Dominant role of the niche in melanocyte stem-cell fate determination. *NATURE* 416:854-860 (2002).
- Pedersen LO, Vetter CS, Mingari MC, Andersen MH, Straten PT, Bröcker EB, Becker JC: Differential expression of inhibitory or activating CD94/NKG2 subtypes on MART-1-reactive T cells in vitiligo versus melanoma: A case report. *J INVEST DERMATOL* 118:595-599 (2002).
- Pedoux R, Lefort K, Cuenin C, Cortes U, Kellner K, Doré JF, Nakazawa H: Specific induction of gadd45 in human melanocytes and melanoma cells after UVB irradiation. *INT J CANCER* 98:811-816 (2002).
- Phillipson RP, Tobi SE, Morris JA, McMillan TJ: UV-A induces persistent genomic instability in human keratinocytes through an oxidative stress mechanism. *FREE RADICAL BIOL MED* 32:474-480 (2002).
- Piercecchi-Marti MD, Mohamed H, Liprandi A, Gambarelli D, Grisoli F, Pellissier JF: Intracranial meningeal melanocytoma associated with ipsilateral nevus of Ota - Case report. *J NEUROSURG* 96:619-623 (2002).
- Provance DW, James TL, Mercer JA: Melanophilin, the product of the leaden locus, is required for targeting of myosin-Va to melanosomes. *TRAFFIC* 3:124-132 (2002).
- Raisova M, Goltz G, Bektas M, Bielawska A, Riebeling C, Hossini AM, Eberle J, Hannun YA, Orfanos CE, Geilen CC: Bcl-2 overexpression prevents apoptosis induced by ceramidase inhibitors in malignant melanoma and HaCaT keratinocytes. *FEBS LETT* 516:47-52 (2002).
- Raposo G, Marks MS: The dark side of lysosome-related organelles: Specialization of the endocytic pathway for melanosome biogenesis. *TRAFFIC* 3:237-248 (2002).
- Rass K, Gutwein P, Welter C, Meineke V, Tilgen W, Reichrath J: DNA mismatch repair enzyme hMSH2 in malignant melanoma: Increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines. *HISTOCHEM J* 33:459-467 (2001).
- Riley PA. Du Temps Perdu a la Recherche. *PIGM CELL RES* 15[2], 135-154. 2002.
- Rudolph P: The dysplastic nevus. An Ariadne's thread through a conceptual labyrinth. *PATHOLOGE* 23:128-134 (2002).
- Rudolph R: Classical and new diagnostic approaches to melanocytic tumors. *PATHOLOGE* 23:89-96 (2002).
- Rufa A, Dotti MT, Galli L, Orrico A, Sicurelli F, Federico A: Spinocerebellar ataxia type 2 (Sca2) associated with retinal pigmentary degeneration. *EUR NEUROL* 47:128-129 (2002).
- Scott G, Leopardi S, Printup S, Madden BC: Filopodia are conduits for melanosome transfer to keratinocytes. *J CELL SCI* 115:1441-1451 (2002).
- Shaffrali FCG, McDonagh AJG, Messenger AG. Hair darkening in porphyria cutanea tarda. *BRIT J DERMATOL* 146[2], 325-329. 2002.
- Sharma S, Wagh S, Govindarajan R: Melanosomal proteins - Role in melanin polymerization. *PIGM CELL RES* 15:127-133 (2002).
- Shimizu K, Kondo R, Sakai K, Takeda N, Nagahata T: The skin-lightening effects of artocarpin on UVB-induced pigmentation. *PLANTA MED* 68:79-81 (2002).
- Siskind V, Darlington S, Green L, Green A: Evolution of melanocytic nevi on the faces and necks of adolescents: A 4 y longitudinal study. *J INVEST DERMATOL* 118:500-504 (2002).

- Steitz J, Brück J, Gambotto A, Knop J, Tüting T: Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. *GENE THERAPY* 9:208-213 (2002).
- Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlov SJ, Easty DJ, Cheong SC, Beach D, DePinho RA, Bennett DC: p16(Ink4a) in melanocyte senescence and differentiation. *J NAT CANCER INST* 94:446-454 (2002).
- Tada A, Pereira E, Beitner-Johnson D, Kavanagh R, Abdel-Malek ZA: Mitogen- and ultraviolet-B-induced signaling pathways in normal human melanocytes. *J INVEST DERMATOL* 118:316-322 (2002).
- Taylor SC. Skin of color: Biology, structure, function, and implications for dermatologic disease. *J AMER ACAD DERMATOL* 46[2], S41-S62. 2002.
- Thaug C, West K, Clark BJ, McKie L, Morgan JE, Arnold K et al. Novel ENU-induced eye mutations in the mouse: models for human eye disease. *HUM MOL GENET* 11[7], 755-767. 2002.
- VandenWijngaard RMJG, Asghar SS, Pijnenborg ACLM, Tigges AJ, Westerhof W, Das PK: Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo. *BRIT J DERMATOL* 146:80-87 (2002).
- vanderGaag EJ, Leccia MT, Dekker SK, Jalbert NL, Amodeo DM, Byers HR: Role of zyxin in differential cell spreading and proliferation of melanoma cells and melanocytes. *J INVEST DERMATOL* 118:246-254 (2002).
- Wellbrock C, Weisser C, Geissinger E, Troppmair J, Scharl M: Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. *J BIOL CHEM* 277:6443-6454 (2002).
- Wilms LC, Zhao C, Snellman E, Segerbäck D, Hemminki K: Measurement of cyclobutane thymidine dimers in melanocytic nevi and surrounding epidermis in human skin in situ. *MUTAGENESIS* 17:189-191 (2002).
- Yoshida M, Hirotsu S, Nakahara M, Uchiwa H, Tomita Y: Histamine is involved in ultraviolet B-induced pigmentation of guinea pig skin. *J INVEST DERMATOL* 118:255-260 (2002).
- Zhang Q, Zhen LJ, Li W, Novak EK, Collinson LM, Jang EK, Haslam RJ, Elliott RW, Swank RT: Cell-specific abnormal prenylation of Rab proteins in platelets and melanocytes of the gunmetal mouse. *BRIT J HAEMATOL* 117:414-423 (2002).
- Zhao CY, Snellman E, Jansen CT, Hemminki K: In situ repair of cyclobutane pyrimidine dimers in skin and melanocytic nevi of cutaneous melanoma patients. *INT J CANCER* 98:331-334 (2002).

MELANOMA & METASTASIS

- Time for a campaign on melanoma. *EUR J CANCER* 38:740 (2002).
- Melanoma: identification of an important early marker. *CLIN GENET* 61:98-99 (2002).
- Alberg A, Gordon GB, Genkinger JM, Hoffman SC, Selvin E, Comstock GW, Helzlsouer KJ: Serum dehydroepiandrosterone and dehydroepiandrosterone sulfate and risk of melanoma or squamous cell carcinoma of the skin. *ANTICANCER RES* 21:4051-4054 (2001).
- Alexander KR, Barnes CS, Fishman GA, Milam AH. Nature of the cone ON-pathway dysfunction in melanoma-associated retinopathy. *INVEST OPHTHALMOL VISUAL SCI* 43[4], 1189-1197. 2002.
- Alfonso M, Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, Pérez R, Vázquez AM: An anti-idiotypic vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. *J IMMUNOL* 168:2523-2529 (2002).
- Allen PJ, Coit DG: The role of surgery for patients with metastatic melanoma. *CURR OPIN ONCOL* 14:221-226 (2002).
- Alves A, Maillolchaud JH, Sauvanet A, O'Toole D, Couvelard A, Ruszniewski P, Belghiti J: Primary melanoma of the esophagus: yield of endosonography in the staging. *GASTROEN CLIN BIOL* 25:1117-1118 (2001).
- Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl KP: Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. *BRIT J OPHTHALMOL* 86:163-167 (2002).
- Atzpodien J, Neuber K, Kamanabrou D, Fluck M, Bröcker EB, Neumann C, Rüniger TM, Schuler G, vondenDriesch P, Müller I, Paul E, Patzelt T, Reitz M: Combination chemotherapy with or without s.c. IL-2 and IFN- α : results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). *BRIT J CANCER* 86:179-184 (2002).
- Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerottini JC, Rammensee HG, Pfreundschuh M, Speiser D, Lévy F: Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. *J IMMUNOL* 168:1717-1722 (2002).
- Balch CM, Mihm MC: Reply to the article "the AJCC staging proposal for cutaneous melanoma: comments by the EORTC Melanoma Group", by D. J. Ruiters et al. (*Ann Oncol* 2001; 12: 9-11). *ANN ONCOL* 13:175-176 (2002).
- Baliellias C, Pagerols X, Curcó N, García-Font M, Forné M, Vives P: Metastatic malignant melanoma presenting as malabsorption. *DIGEST DIS SCI* 47:122-124 (2002).
- Ballo MT, Strom EA, Zagars GK, Bedikian AY, Prieto VG, Mansfield PF, Lee JE, Gershenwald JE, Ross MI: Adjuvant irradiation for axillary metastases from malignant melanoma. *INT J RADIAT ONCOL BIOL PHYS* 52:964-972 (2002).
- Barth RF, Yang WL, Bartus RT, Rotaru JH, Ferketich AK, Moeschberger ML, Nawrocky MM, Coderre JA, Rofstad EK: Neutron capture therapy of intracerebral melanoma: Enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. *INT J RADIAT ONCOL BIOL PHYS* 52:858-868 (2002).

- Bilbao P, delOlmo M, Alonso-Varona A, Castro B, Bilbao J, Palomares T: L-2-Oxothiazolidine-4-carboxylate reverses the tumour growth-promoting effect of interleukin-2 and improves the anti-tumour efficacy of biochemotherapy in mice bearing B16 melanoma liver metastases. *MELANOMA RES* 12:17-26 (2002).
- Biswas J, Krishnakumar S, Shanmugam MP: Uveal melanoma in Asian Indians: A clinicopathological study. *ARCH OPHTHALMOL* 120:522-523 (2002).
- Blackwood MA, Holmes R, Synnestvedt M, Young M, George G, Yang H, Elder DE, Schuchter LM, Guerry D, Ganguly A: Multiple primary melanoma revisited. *CANCER* 94:2248-2255 (2002).
- Bold RJ: Elective lymph node dissection in patients with melanoma - Systematic review and meta-analysis of randomized controlled trials - Invited critique. *ARCH SURG* 137:461 (2002).
- Boniol M, Sallin J, Doré JF: Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. *CANCER* 94:1902-1903 (2002).
- Brantley MA, Worley L, Harbour JW: Altered expression of Rb and p53 in uveal melanomas following plaque radiotherapy. *AMER J OPHTHALMOL* 133:242-248 (2002).
- Brown LM, Welch DR, Rannels DE, Rannels SR: Partial pneumonectomy enhances melanoma metastasis to mouse lungs. *CHEST* 121:28S-29S (2002).
- Buchsbaum JC, Suh JH, Lee SY, Chidel MA, Greskovich JF, Barnett GH: Survival by Radiation Therapy Oncology Group recursive partitioning analysis class and treatment modality in patients with brain metastases from malignant melanoma - A retrospective study. *CANCER* 94:2265-2272 (2002).
- Carli P, DeGiorgi V, Nardini P, Mannone F, Palli D, Giannotti B: Melanoma detection rate and concordance between self-skin examination and clinical evaluation in patients attending a pigmented lesion clinic in Italy. *BRIT J DERMATOL* 146:261-266 (2002).
- Carsana M, Tragni G, Nicolini G, Bersani M, Parmiani G, Anichini A, Sun YS, Möller P, Schadendorf D, Sensi ML: Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine. *CANCER GENE THERAPY* 9:243-253 (2002).
- Chao C, McMasters KM: Update on the use of sentinel node biopsy in patients with melanoma: who and how. *CURR OPIN ONCOL* 14:217-220 (2002).
- Clarijs R, Otte-Höller I, Ruiter DJ, deWaal RMW: Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. *INVEST OPHTHALMOL VISUAL SCI* 43:912-918 (2002).
- Coldiron B, Dinehart S: Sentinel-node technique will change the design of clinical trials in malignant melanoma. *J CLIN ONCOL* 20:2208-2209 (2002).
- Cooper JS, Chang WS, Oratz R, Shapiro RL, Roses DF: Elective radiation therapy for high-risk malignant melanomas. *CANCER J* 7:498-502 (2001).
- Creager AJ, Pitman MB, Geisinger KR: Cytologic features of clear cell sarcoma (malignant melanoma) of soft parts - A study of fine-needle aspirates and exfoliative specimens. *AMER J CLIN PATHOL* 117:217-224 (2002).
- Crotty KA, Scolyer RA, Li LXL, Palmer AA, Wang LX, McCarthy SW: Spitz naevus versus Spitzoid melanoma: When and how can they be distinguished? *PATHOLOGY* 34:6-12 (2002).
- Curless RG, Toledano SR, Ragheb J, Cleveland WW, Falcone S: Hematogenous brain metastasis in children. *PEDIAT NEUROL* 26:219-221 (2002).
- Dalton SR, Baptista MA, Libow LF, Elston DM: Lichenoid tissue reaction in malignant melanoma - A potential diagnostic pitfall. *AMER J CLIN PATHOL* 117:766-770 (2002).
- Dees C, Harkins J, Petersen MG, Fisher WG, Wachter EA: Treatment of murine cutaneous melanoma with near infrared light. *PHOTOCHEM PHOTOBIO* 75:296-301 (2002).
- Demunter A, Libbrecht L, Degreef H, DeWolf-Peeters C, vandenOord JJ: Loss of membranous expression of β -catenin is associated with tumor progression in cutaneous melanoma and rarely caused by Exon 3 mutations. *MODERN PATHOL* 15:454-461 (2002).
- deWit NJW, Weidle UH, Ruiter DJ, vanMuijen GNP: Expression profiling of MMA-1a and splice variant MMA-1b: New cancer/testis antigens identified in human melanoma. *INT J CANCER* 98:547-553 (2002).
- deWit NJW, Burtscher HJ, Weidle UH, Ruiter DJ, vanMuijen GNP: Differentially expressed genes identified in human melanoma cell lines with different metastatic behaviour using high density oligonucleotide arrays. *MELANOMA RES* 12:57-69 (2002).
- Dhawan P, Richmond A: A novel NF- κ B-inducing kinase-MAPK signaling pathway up-regulates NF- κ B activity in melanoma cells. *J BIOL CHEM* 277:7920-7928 (2002).
- Dobrowolski R, Hein R, Buettner R, Bosserhoff AK: Loss of p14(ARF) expression in melanoma. *ARCH DERMATOL RES* 293:545-551 (2002).
- Dong YB, Yang HL, Elliott MJ, McMasters KM: Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. *CANCER RES* 62:1776-1783 (2002).
- Drukala J, Rajwa B, Pietrzakowski Z: Effect of daunomycin on expression of CD44H protein in HTB140 melanoma cells in vitro. *ANTICANCER RES* 21:3793-3798 (2001).
- Eggermont AMM: European approach to the treatment of malignant melanoma. *CURR OPIN ONCOL* 14:205-211 (2002).

- Eggermont AMM, Keilholz U, Autier P, Ruiter DJ, Lehmann F, Lienard D: The EORTC Melanoma Group: a comprehensive melanoma research programme by clinicians and scientists. *EUR J CANCER* 38:S114-S119 (2002).
- Eicher SA, Clayman GL, Myers JN, Gillenwater AM: A prospective study of Intraoperative lymphatic mapping for head and neck cutaneous melanoma. *ARCH OTOLAR HEAD NECK SURGERY* 128:241-246 (2002).
- Eleveld-Trancíková D, Kúdela P, Majerciak V, Regendová M, Zelník V, Pastorek J, Pastoreková S, Bízík J: Suppression subtractive hybridisation to isolate differentially expressed genes involved in invasiveness of melanoma cell line cultured under different conditions. *INT J ONCOL* 20:501-508 (2002).
- Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA: Loss of MDA-7 expression with progression of melanoma. *J CLIN ONCOL* 20:1069-1074 (2002).
- Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O: Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma. *ANTI CANCER DRUG* 13:169-172 (2002).
- Eskelin S, Kivelä T: Mode of presentation and time to treatment of uveal melanoma in Finland. *BRIT J OPHTHALMOL* 86:333-338 (2002).
- Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial. *J CLIN ONCOL* 20:2045-2052 (2002).
- Farrokh D, Fransen P, Faverly D: MR findings of a primary intramedullary malignant melanoma: Case report and literature review. *AMER J NEURORADIOL* 22:1864-1866 (2001).
- Fata F, Mirza A, Bernath A: Skin lesions in melanoma and Kaposi's sarcoma - Case 3. Familial classic Mediterranean Kaposi's sarcoma. *J CLIN ONCOL* 20:1415-1418 (2002).
- Fei XF, Wang BX, Tashiro S, Li TJ, Ma JS, Ikejima T: Apoptotic effects of ginsenoside Rh-2 on human malignant melanoma A375-S2 cells. *ACTA PHARMACOL SIN* 23:315-322 (2002).
- Filie AC, Simsir A, Fetsch P, Abati A: Melanoma metastatic to the breast - Utility of fine needle aspiration and immunohistochemistry. *ACTA CYTOL* 46:13-18 (2002).
- Firat H, Zennou V, Garcia-Pons F, Ginhoux F, Cochet M, Danos O, Lemonnier FA, Langlade-Demoyen P: Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. *J GENE MED* 4:38-45 (2002).
- Friedman T, Friedman M, Weitzen R, Scapa E: Generalized and mucosal melanosis associated with ultra-late recurrence of malignant melanoma. *ENDOSCOPY* 34:352 (2002).
- Fukami A, Iijima K, Hayashi M, Komiyama K, Omura S: Macrophelide B suppressed metastasis through inhibition of adhesion of sLe(x)/E-selectin molecules. *BIOCHEM BIOPHYS RES COMMUN* 291:1065-1070 (2002).
- Garbe C, Ellwanger U, Tronnier M, Brocker EB, Orfanos CE: The new American Joint Committee on Cancer staging system for cutaneous melanoma - A critical analysis based on data of the German Central Malignant Melanoma Registry. *CANCER* 94:2305-2307 (2002).
- Ge XK, Fu YM, Meadows GG: U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. *CANCER LETT* 179:133-140 (2002).
- Geertsen R, Boni R, Blaszyk R, Romero P, Betts D, Rimoldi D, Hong X, Laine E, Willers J, Dummer R: Loss of single HLA Class I allospecificities in melanoma cells due to selective genomic abbreviations. *INT J CANCER* 99:82-87 (2002).
- Giermasz A, Grzela T, Nowis D, Makowski M, Czajka A, Stoklosa T, Lasek W, Dabrowska A, Wiznerowicz M, Mackiewicz A, Jakóbsiak M: Butyric acid enhances in vivo expression of hTNF- α in transduced melanoma cell line. *ANTICANCER RES* 21:4001-4004 (2001).
- Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry D, Sagebiel R, Elder DE, Tucker MA: Rarity of CDK4 germline mutations in familial melanoma. *MELANOMA RES* 12:51-55 (2002).
- Guadagni S, Russo F, Rossi CR, Pilati PL, Miotto D, Fiorentini G, Deraco M, Santinami M, Palumbo G, Valenti M, Amicucci G: Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. *AMER J SURG* 183:28-36 (2002).
- Guan XY, Zhang HE, Zhou H, Sham JST, Fung JMW, Trent JM: Characterization of a complex chromosome rearrangement involving 6q in a melanoma cell line by chromosome microdissection. *CANCER GENET CYTOGENET* 134:65-70 (2002).
- Habib G, Saliba WR: Tumor lysis syndrome after hydrocortisone treatment in metastatic melanoma: A case report and review of the literature. *AMER J MED SCI* 323:155-157 (2002).
- Hanson IM, Banerjee SS, Menasce LP, Prescott RJ: A study of eleven cutaneous malignant melanomas, in adults with small-cell morphology: emphasis on diagnostic difficulties and unusual features. *HISTOPATHOLOGY* 40:187-195 (2002).
- Hawkins WG, Gold JS, Blachere NE, Bowne WB, Hoos A, Lewis JJ, Houghton AN: Xenogeneic DNA immunization in melanoma models for minimal residual disease. *J SURG RES* 102:137-143 (2002).
- Hazard LJ, Sause WT, Noyes RD: Combined adjuvant radiation and interferon-alpha 2B therapy in high-risk melanoma patients: The potential for increased radiation toxicity. *INT J RADIAT ONCOL BIOL PHYS* 52:796-800 (2002).
- Hegerfeldt Y, Tusch M, Bröcker EB, Friedl P: Collective cell movement in primary melanoma explants: Plasticity of cell-cell interaction, ss1-integrin function, and migration strategies. *CANCER RES* 62:2125-2130 (2002).
- Hendrix MJC, Seftor REB, Seftor EA, Gruman LM, Lee LML, Nickoloff BJ, Miele L, Sheriff DD, Schatteman GC: Transendothelial function of human metastatic melanoma cells: Role of the microenvironment in cell-fate determination. *CANCER RES* 62:665-668 (2002).

- Herlyn M: Emerging concepts and technologies in melanoma research. *MELANOMA RES* 12:3-8 (2002).
- Hermann RM, Pradier O, Lauritzen K, Ott M, Schmidberger H, Hess CF: Does escalation of the apical dose change treatment outcome in β -radiation of posterior choroidal melanomas with Ru-106 plaques? *INT J RADIAT ONCOL BIOL PHYS* 52:1360-1366 (2002).
- Hofbauer GFL, Böni R, Simmen D, Mihic D, Nestle FO, Burg G, Dummer R: Histological, immunological and molecular features of a nasal mucosa primary melanoma associated with nasal melanosis. *MELANOMA RES* 12:77-82 (2002).
- Hossain N, Zapata A, Wilstermann M, Nilsson UJ, Magnusson G. Synthesis of GD3-lactam: a potential ligand for the development of an anti-melanoma vaccine. *CARBOHYD RES* 337[7], 569-580. 2002.
- Howell WM, Turner SJ, Collins A, Bateman AC, Theaker JM: Influence of TNF α and LT α single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population. *EUR J IMMUNOGENET* 29:17-23 (2002).
- Huang SY, Bucana CD, VanArsdall M, Fidler IJ: Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. *ONCOGENE* 21:2504-2512 (2002).
- Hunzelmann N, Kurschat P, Hani N, Jarisch A, Mauch C: Applicability of reference values for the determination of serum S100 protein as a marker of malignant melanoma in children. *BRIT J DERMATOL* 146:536-537 (2002).
- Iscovich J, Abdulrazik M, Cour C, Fischbein A, Pe'er J, Goldgar DE: Prevalence of the BRCA2 6174 del T mutation in Israeli uveal melanoma patients. *INT J CANCER* 98:42-44 (2002).
- Iwamoto S, Burrows RC, Kalina RE, George D, Boehm M, Bothwell MA, Schmidt R: Immunophenotypic differences between uveal and cutaneous melanomas. *ARCH OPHTHALMOL* 120:466-470 (2002).
- Jaafari MR, Foldvari M: Targeting of liposomes to melanoma cells with high levels of ICAM-1 expression through adhesive peptides from immunoglobulin domains. *J PHARM SCI* 91:396-404 (2002).
- Jäger E, Höhn H, Necker A, Förster R, Karbach J, Freitag K et al. Peptide-specific CD8+T-cell evolution in vivo: Response to peptide vaccination with Melan-A/MART-I. *INT J CANCER* 98[3], 376-388. 2002.
- Jaroszewski DE, Pockaj BA, DiCaudo DJ, Bite U: The clinical behavior of desmoplastic melanoma. *AMER J SURG* 182:590-595 (2001).
- Jelic S, Babovic N, Kovcin V, Milicevic N, Milanovic N, Popov I, Radosavljevic D: Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. *MELANOMA RES* 12:91-98 (2002).
- Johansen C, Boice JD, McLaughlin JK, Christensen HC, Olsen JH: Mobile phones and malignant melanoma of the eye. *BRIT J CANCER* 86:348-349 (2002).
- Jones R, Gore E, Mieler W, Murray K, Gillin M, Albano K, Erickson B: Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: Dose and dose rate effects. *INT J RADIAT ONCOL BIOL PHYS* 52:989-995 (2002).
- Kalady MF, White DC, Fields RC, Coleman RE, Schuler FR, Seigler HF, Tyler DS: Validation of delayed sentinel lymph node mapping for melanoma. *CANCER J* 7:503-508 (2001).
- Kashani-Sabet M, Sagebiel RW, Ferreira CMM, Nosrati M, Miller JR: Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. *J CLIN ONCOL* 20:1826-1831 (2002).
- Kilbridge KL, Cole BF, Kirkwood JM, Haluska FG, Atkins MA, Ruckdeschel JC, Sock DE, Nease RF, Weeks JC: Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alfa-2b for high-risk melanoma patients using intergroup clinical trial data. *J CLIN ONCOL* 20:1311-1318 (2002).
- Kirkham N: Small cell melanoma. *HISTOPATHOLOGY* 40:196-198 (2002).
- Kirkwood JM, Agarwala SS, Ibrahim J, Manola J, Sondak VK, Ernstoff MS, Ross MK: Sentinel-node technique will change the design of clinical trials in malignant melanoma - Reply. *J CLIN ONCOL* 20:2209-2210 (2002).
- Kirkwood JM, Ibrahim JG, Sondak VK, Ernstoff MS, Ross M: Interferon alfa-2a for melanoma metastases. *LANCET* 359:978-979 (2002).
- Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U: Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. *MODERN PATHOL* 15:426-433 (2002).
- Kozłowska K, Cichorek M, Zarzeczna M: A study on nitric oxide secretion by transplantable melanoma cell lines with regard to their spontaneous apoptosis. *NEOPLASMA* 48:496-500 (2001).
- Krasagakis K, Fimmel S, Genten D, Eberle J, Quas P, Ziegler W, Haller H, Orfanos CE: Lack of protein kinase C (PKC)- β and low PKC- α , - δ , - ϵ , and - ζ isozyme levels in proliferating human melanoma cells. *INT J ONCOL* 20:865-871 (2002).
- Kretschmer L, Neumann C: Sentinel-node technique will change the design of clinical trials in malignant melanoma. *J CLIN ONCOL* 20:2208 (2002).
- Lamberg L: "Epidemic" of malignant melanoma - True increase or better detection? *JAMA J AM MED ASSN* 287:2201 (2002).
- Laquis SJ, Freeman JM, Fleming JC, Wilson MW, Haik BG: A rapidly growing choroidal melanoma. *AMER J OPHTHALMOL* 133:580-581 (2002).
- Lawrenson ID, Wimmer-Kleikamp SH, Lock P, Schoenwaelder SM, Down M, Boyd AW, Alewood PF, Lackmann M: Ephrin-A5 induces rounding, blebbing and deadhesion of EphA3-expressing 293T and melanoma cells by CrkII and Rho-mediated signalling. *J CELL SCI* 115:1059-1072 (2002).

- Lee HY, Bae GU, Jung ID, Lee JS, Kim YK, Noh SH, Stracke ML, Park CG, Lee HW, Han JW: Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase η in human melanoma cells. *FEBS LETT* 515:137-140 (2002).
- LeGal FA, Prevost-Blondel A, Lengagne R, Bossus M, Farace F, Chaboissier A, Gras-Masse H, Engelhard VH, Guillet JG, Gahéry-Ségard H: Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinical study. *INT J CANCER* 98:221-227 (2002).
- Lens MB, Dawes M: Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. *J CLIN ONCOL* 20:1818-1825 (2002).
- Lens MB, Dawes M, Goodacre T, Newton-Bishop JA: Elective lymph node dissection in patients with melanoma - Systematic review and meta-analysis of randomized controlled trials. *ARCH SURG* 137:458-461 (2002).
- Linard B, Bézieau S, Benlalam H, Labarrière N, Guilloux Y, Diez E, Jotereau F: A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. *J IMMUNOL* 168:4802-4808 (2002).
- Lougheed JC, Domaille PJ, Handel TM: Solution structure and dynamics of melanoma inhibitory activity protein. *J BIOMOL NMR* 22:211-223 (2002).
- Mackie BS, Mackie LE: Etiology and prevention of melanoma. *NUTR CANCER* 40:211-213 (2001).
- Mackie RM, Fleming C, McMahon AD, Jarrett P: The use of the dermatoscope to identify early melanoma using the three-colour test. *BRIT J DERMATOL* 146:481-484 (2002).
- Mah-Becherel MCM, Céraline J, Deplanque G, Chenard MP, Bergerat JP, Cazenave JP, Klein-Soyer C: Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model. *BRIT J CANCER* 86:803-810 (2002).
- Mahabir S, Coit D, Liebes L, Brady MS, Lewis JJ, Roush G, Nestle M, Fry D, Berwick M: Randomized, placebo-controlled trial of dietary supplementation of α -tocopherol on mutagen sensitivity levels in melanoma patients: a pilot trial. *MELANOMA RES* 12:83-90 (2002).
- Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C, Melani C, Belli F, Arienti F, Colombo MP, Parmiani G: Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. *CANCER IMMUNOL IMMUNOTHER* 51:9-14 (2002).
- Malaguarnera M, Vinci M, Pistone G: Malignant melanoma of nasal cavity: Case report and review of the literature. *CANCER BIOTHER RADIOPHARM* 17:29-34 (2002).
- Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L, Mandelboim O: CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. *J IMMUNOL* 168:2803-2810 (2002).
- Martín F, Chowdhury S, Neil S, Phillippis N, Collins MK: Envelope-targeted retrovirus vectors transduce melanoma Xenografts but not spleen or liver. *MOL THER* 5:269-274 (2002).
- Matarrese P, DiBiase L, Santodonato L, Straface E, Mecchia M, Ascione B, Parmiani G, Belardelli F, Ferrantini M, Malorni W: Type I interferon gene transfer sensitizes melanoma cells to apoptosis via a target activity on mitochondrial function. *AMER J PATHOL* 160:1507-1520 (2002).
- Mehta RR, Bratescu L, Graves JM, Shilkaitis A, Green A, Mehta RG, DasGupta TK: In vitro transformation of human congenital naevus to malignant melanoma. *MELANOMA RES* 12:27-33 (2002).
- Merkel S, Meyer T, Papadopoulos T, Schuler G, Göhl J, Hohenberger W, Hermanek P: Testing a new staging system for cutaneous melanoma proposed by the American Joint Committee on Cancer. *EUR J CANCER* 38:517-526 (2002).
- Merlin JL, Marchal S, Ramacci C, Berlion M, Poullain MG: Enhancement of fotemustine (Muphoran(R)) cytotoxicity by amifostine in malignant melanoma cell lines. *ANTI CANCER DRUG* 13:141-147 (2002).
- Mingione V, Oliveira M, Prasad D, Steiner M, Steiner L: Gamma surgery for melanoma metastases in the brain. *J NEUROSURG* 96:544-551 (2002).
- Morvan D, Demidem A, Papon J, DeLatour M, Madelmont JC: Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor sampled. *CANCER RES* 62:1890-1897 (2002).
- Nakamura T, Sato K, Hamada H: Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. *HUM GENE THER* 13:613-626 (2002).
- Nakao K, Sugiyama H, Makino E, Matsuura H, Ohmoto A, Sugimoto T, Ichikawa H, Wada J, Yamasaki Y, Makino H: Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma. *NEPHRON* 90:498-500 (2002).
- Nishimori H, Yasoshima T, Hata F, Denno R, Yanai Y, Nomura H, Tanaka H, Kamiguchi K, Sato N, Hirata K: A novel nude mouse model of liver metastasis and peritoneal dissemination from the same human pancreatic cancer line. *PANCREAS* 24:242-250 (2002).
- Ohno T, Inoue M, Ogihara Y: Cytotoxic activity of gallic acid against liver metastasis of mastocytoma cells P-815. *ANTICANCER RES* 21:3875-3880 (2001).
- Okada Y, Okada N, Nakagawa S, Mizuguchi H, Kanehira M, Nishino N, Takahashi K, Mizuno N, Hayakawa T, Mayumi T: Fiber-mutant technique can augment gene transduction efficacy and anti-tumor effects against established murine melanoma by cytokine-gene therapy using adenovirus vectors. *CANCER LETT* 177:57-63 (2002).

- Olie RA, Hafner C, Küttel R, Sigrist B, Willers J, Dummer R, Hall J, Stahel RA, Zangemeister-Wittke U: Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. *J INVEST DERMATOL* 118:505-512 (2002).
- Papadopoulos S, Benter T, Anastassiou G, Pape M, Gerhard S, Bornfeld N, Ludwig WD, Dörken B: Assessment of genomic instability in breast cancer and uveal melanoma by random amplified polymorphic DNA analysis. *INT J CANCER* 99:193-200 (2002).
- Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H, Stewart AL, Balachandran S, Roth JA, Hunt KK, Swisher SG: Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). *CANCER RES* 62:2239-2243 (2002).
- Patel P, Levin K, Waltz K, Helm KF: Myxoid melanoma: Immunohistochemical studies and a review of the literature. *J AMER ACAD DERMATOL* 46:264-270 (2002).
- Patel SG, Coit DG, Shaha AR, Brady MS, Boyle JO, Singh B, Shah JP, Kraus DH: Sentinel lymph node biopsy for cutaneous head and neck melanomas. *ARCH OTOLAR HEAD NECK SURGERY* 128:285-291 (2002).
- Pizzichetta MA, Canzonieri V, Gatti A, deGiacomi C, Trevisan G, Veronesi A, Soyer HP: Skin lesions in melanoma and Kaposi's sarcoma - Case 2. Dermoscopic features of metastases from cutaneous melanoma mimicking benign nevi and primary melanoma. *J CLIN ONCOL* 20:1412-1415 (2002).
- Poetsch M, Dittberner T, Woenckhaus C: Frameshift mutations of RIZ, but no point mutations in RIZ1 exons in malignant melanomas with deletions in 1p36. *ONCOGENE* 21:3038-3042 (2002).
- Pujades C, Guez-Guez B, Dunon D: Melanoma Cell Adhesion Molecule (MCAM) expression in the myogenic lineage during early chick embryonic development. *INT J DEV BIOL* 46:263-266 (2002).
- Rao UNM, Ibrahim J, Flaherty LE, Richards J, Kirkwood JM: Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: Pathologic corollary of eastern cooperative oncology group trial E1690. *J CLIN ONCOL* 20:2053-2057 (2002).
- Ridolfi L, Ridolfi R: Preliminary experiences of Intralesional immunotherapy in cutaneous metastatic melanoma. *HEPATO GASTROENTEROL* 49:335-339 (2002).
- Ridolfi R, Chiarion-Sileni V, Guido M, Romanini A, Labianca R, Freschi A, LoRe G, Nortilli R, Brugnara S, Vitali P, Nanni O: Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian Multicenter phase III Randomized Clinical Trial. *J CLIN ONCOL* 20:1600-1607 (2002).
- Roberts DLL, Anstey AV, Barlow RJ, Cox NH, Bishop JAN, Corrie PG, Evans J, Gore ME, Hall PN, Kirkham N: UK guidelines for the management of cutaneous melanoma. *BRIT J DERMATOL* 146:7-17 (2002).
- Rochlitz C, Dreno B, Jantschke P, Cavalli F, Squiban P, Acres B, Baudin M, Escudier B, Heinzerling L, Morant R, Herrmann R, Dietrich PY, Dummer R: Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels. *CANCER GENE THERAPY* 9:289-295 (2002).
- Rofstad EK, Tunheim SH, Mathiesen B, Graff BA, Halsor EF, Nilsen K, Galappathi K: Pulmonary and lymph node metastasis is associated with primary tumor interstitial fluid pressure in human melanoma xenografts. *CANCER RES* 62:661-664 (2002).
- Rofstad EK, Halsor EF: Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. *BRIT J CANCER* 86:301-308 (2002).
- Salti GI, Kansagra A, Warso MA, Ronan SG, DasGupta TK: Clinical node-negative thick melanoma. *ARCH SURG* 137:291-295 (2002).
- Santini D, Tonini G, Vincenzi B, Murace R, Ferranti G, Baldi A: Skin lesions in melanoma and Kaposi's sarcoma - Case 1. Detection of circulating malignant cells by RT-PCR in a case of cutaneous melanoma in complete regression. *J CLIN ONCOL* 20:1411-1412 (2002).
- Schmid-Wendtner MH, Partscht K, Korting HC, Volkenandt M: Improved differentiation of benign and malignant lymphadenopathy in patients with cutaneous melanoma by contrast-enhanced color Doppler sonography. *ARCH DERMATOL* 138:491-497 (2002).
- Schulten HJ, Gunawan B, Otto F, Hassmann R, Hallermann C, Noebel A, Füzesi L: Cytogenetic characterization of complex karyotypes in seven established melanoma cell lines by multiplex fluorescence in situ hybridization and DAPI banding. *CANCER GENET CYTOGENET* 133:134-141 (2002).
- Shenoy BD, Venkatesh M, Udupa N: Optimization and performance evaluation of peptide-loaded monolithic poly-ε-caprolactone microspheres in mice bearing melanoma B16F1. *PHARMAZIE* 57:256-260 (2002).
- Shevde LA, Samant RS, Goldberg SF, Sikaneta T, Alessandrini A, Donahue HJ, Mauger DT, Welch DR: Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. *EXP CELL RES* 273:229-239 (2002).
- Shi YF, Parhar RS, Zou MJ, Al Mohanna FA, Paterson MC: Gene therapy of melanoma pulmonary metastasis by intramuscular injection of plasmid DNA encoding tissue inhibitor of metalloproteinases-1. *CANCER GENE THERAPY* 9:126-132 (2002).
- Shields CL: Conjunctival melanoma. *BRIT J OPHTHALMOL* 86:127 (2002).
- Shukuwa T, Katayama I, Koji T: Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. *MODERN PATHOL* 15:387-396 (2002).

- Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest Oncology Group. *J CLIN ONCOL* 20:2058-2066 (2002).
- Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK: Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Impact of HLA class I antigen expression on outcome. *J CLIN ONCOL* 20:2067-2075 (2002).
- Speiser DE, Liénard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P et al. In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. *EUR J IMMUNOL* 32[3], 731-741. 2002.
- Stitt AW, Gardiner TA: Anti-angiogenic therapy for uveal melanoma - more haste, less speed. *BRIT J OPHTHALMOL* 86:368-369 (2002).
- StPeter SD, Roarke MC, Conley CR, Pockaj BA: Sentinel lymph node biopsy demonstrating concomitant melanoma and mantle cell lymphoma. *SURGERY* 131:216-218 (2002).
- Tanaka M, Kaneda Y, Fujii S, Yamano T, Hashimoto K, Huang SKS, Hoon DSB: Induction of a systemic immune response by a polyvalent melanoma-associated antigen DNA vaccine for prevention and treatment of malignant melanoma. *MOL THER* 5:291-299 (2002).
- Tanaka S: Cryosurgery for malignant melanoma. *BASICS OF CRYOSURGERY*. 289-293 (2001).
- Tanita M, Kikuchi-Numagami K, Ogoshi K, Suzuki T, Tabata N, Kudoh K, Suetake T, Takahashi T, Tagami H: Malignant melanoma arising from cutaneous bronchogenic cyst of the scapular area. *J AMER ACAD DERMATOL* 46:S19-S21 (2002).
- Tannous ZS, Mihm MC, Flotte TJ, González S: In vivo examination of lentigo maligna and malignant melanoma in situ, lentigo maligna type by near-infrared reflectance confocal microscopy: Comparison of in vivo confocal ages with histologic sections. *J AMER ACAD DERMATOL* 46:260-263 (2002).
- Touab M, Villena J, Barranco C, Arumí-Uría M, Bassols A: Versican is differentially expressed in human melanoma and may play a role in tumor development. *AMER J PATHOL* 160:549-557 (2002).
- Tsuji T, Kawada Y, Kai-Murozono M, Komatsu S, Han SA, Takeuchi K, Mizushima H, Miyazaki K, Irimura T: Regulation of melanoma cell migration and invasion by laminin-5 and $\alpha 3 \beta 1$ integrin (VLA-3). *CLIN EXP METASTAS* 19:127-134 (2002).
- Uwatoko N, Tokunaga T, Hatanaka H, Osada D, Kawakami T, Yamazaki H, Abe Y, Kijima H, Ueyama Y, Nakamura M: Expression of interleukin-10 is inversely correlated with distant metastasis of renal cell carcinoma. *INT J ONCOL* 20:729-733 (2002).
- Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemisen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Liénard D, Keilholz U: Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. *CANCER RES* 62:1743-1750 (2002).
- Vetter CS, Groh V, Straten PT, Spies T, Bröcker EB, Becker JC: Expression of stress-induced MHC class I related chain molecules on human melanoma. *J INVEST DERMATOL* 118:600-605 (2002).
- Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ, Dixit VM: SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-LAP). *J BIOL CHEM* 277:12275-12279 (2002).
- Wachsberger PR, Burd R, Wahl ML, Leeper DB: Betulinic acid sensitization of low pH adapted human melanoma cells to hyperthermia. *INT J HYPERTHER* 18:153-164 (2002).
- Wachsberger PR, Gressen EL, Bhala A, Bobyock SB, Storck C, Coss RA, Berd D, Leeper DB: Variability in glucose transporter-1 levels and hexokinase activity in human melanoma. *MELANOMA RES* 12:35-43 (2002).
- Waldmann V, Wacker J, Deichmann M: Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. *MELANOMA RES* 12:45-50 (2002).
- Wandel E, Raschke A, Hildebrandt G, Eberle J, Dummer R, Anderegg U, Saalbach A: Fibroblasts enhance the invasive capacity of melanoma cells in vitro. *ARCH DERMATOL RES* 293:601-608 (2002).
- Weidinger SE, Hein R, Ring J, Köhn FM: Endocrinologic changes in male patients with melanoma during interferon alfa-2b therapy. *ARCH DERMATOL* 138:541-542 (2002).
- Weinreich DM, Rosenberg SA: Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. *J IMMUNOTHER* 25:185-187 (2002).
- Whitehead RP, Unger JM, Flaherty LE, Kraut EH, Mills GM, Klein CE, Chapman RA, Doolittle GC, Hammond N, Sondak VK: A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy - Southwest Oncology Group study. *INVEST NEW DRUG* 20:105-111 (2002).
- Whiteman DC, Zhou XP, Cummings MC, Pavey S, Hayward NK, Eng C: Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. *INT J CANCER* 99:63-67 (2002).
- Wilson D, Klein ML: Cryotherapy as a primary treatment for choroidal melanoma. *ARCH OPHTHALMOL* 120:400-403 (2002).
- Wilson DJ, Klein ML: Choroidal melanoma treated with cryotherapy. *ARCH OPHTHALMOL* 120:393-395 (2002).
- With S, Bille F, Koenig S, Wehrli N, Miconnet I, Levy F, Diggelmann H, Romero P, Acha-Orbea H: Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanoma tumor antigen. *INT J CANCER* 99:201-206 (2002).

Zacast AC, Besser M, Stevens G, Thompson JR, McCarthy WH, Culjak G: Surgical management of cerebral metastases from melanoma: outcome in 147 patients treated at a single institution over two decades. *J NEUROSURG* 96:552-558 (2002).

MSH, POMC, GROWTH FACTORS & RECEPTORS

- Alrubaian J, Danielson P, Walker D, Dores RM: Cladistic analysis of anuran POMC sequences. *PEPTIDES* 23:443-452 (2002).
- Arslan SO, Zerim M, Vural H, Coskun A: The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats. *J PINEAL RES* 32:21-25 (2002).
- Bayer L, Mairet-Coello G, Risold PY, Griffond B: Orexin/hypocretin neurons: chemical phenotype and possible interactions with melanin-concentrating hormone neurons. *REGUL PEPTIDES* 104:33-39 (2002).
- Bednarek MA, Tan C, Hreniuk DL, Palyha OC, MacNeill DJ, VanderPloeg LHY, Howard AD, Feighner SD: Synthesis and biological evaluation in vitro of a selective, high potency peptide agonist of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1. *J BIOL CHEM* 277:13821-13826 (2002).
- Boyd SR, Tan D, Bunce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA: Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. *BRIT J OPHTHALMOL* 86:448-452 (2002).
- Boyd SR, Tan DSW, deSouza L, Neale MH, Myatt NE, Alexander RA, Robb M, Hungerford JL, Cree IA: Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. *BRIT J OPHTHALMOL* 86:440-447 (2002).
- Böhm M, Schiller M, Ständer S, Seltmann H, Li Z, Brzoska T, Metz D, Schiöth HB, Skottner A, Seiffert K, Zouboulis CC, Luger TA: Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. *J INVEST DERMATOL* 118:533-539 (2002).
- Bressac-de-Paillerets B, Avril MF, Chompret A, Demenais F: Genetic and environmental factors in cutaneous malignant melanoma. *BIOCHIMIE* 84:67-74 (2002).
- Chen JQ, Cheng Z, Miao YB, Jurisson SS, Quinn TP: α -melanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting. *CANCER* 94:1196-1201 (2002).
- Cobb CS, Metz JR, Flik G, Williamson R: Melanocyte-stimulating hormone plasma levels and environmental illumination in the cuttlefish, *Sepia officinalis*: A role for the neurosecretory system of the vena cava in cephalopods. *GEN COMP ENDOCRINOL* 125:435-440 (2002).
- Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, Alexander HR: Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. *INT J CANCER* 99:149-153 (2002).
- Fuzii HT, Travassos LR: Transient resistance to B16F10 melanoma growth and metastasis in CD43^{-/-} mice. *MELANOMA RES* 12:9-16 (2002).
- Galas L, Tonon MC, Beaujean D, Fredriksson R, Larhammar D, Lihmann I, Jegou S, Fournier A, Chartrel N, Vaudry H: Neuropeptide Y inhibits spontaneous α -melanocyte-stimulating hormone (α -MSH) release via a Y-5 receptor and suppresses thyrotropin-releasing hormone-induced α -MSH secretion via a Y-1 receptor in frog melanotrope cells. *ENDOCRINOLOGY* 143:1686-1694 (2002).
- García-Hernández ML, Hernández-Pando R, Gariglio P, Berumen J: Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. *IMMUNOLOGY* 105:231-243 (2002).
- Gautam A, Waldrep JC, Densmore CL, Koshkina N, Melton S, Roberts L, Gilbert B, Knight V: Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. *GENE THERAPY* 9:353-357 (2002).
- Gervelas C, Avramoglou T, Crépin M, Jozefonvicz J: Growth inhibition of human melanoma tumor cells by the combination of sodium phenylacetate (NaPA) and substituted dextrans and one NaPA-dextran conjugate. *ANTI CANCER DRUG* 13:37-45 (2002).
- Grieco P, Han GX, Weinberg D, MacNeil T, VanderPloeg LHT, Hruby VJ: Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. *BIOCHEM BIOPHYS RES COMMUN* 292:1075-1080 (2002).
- Griffond B, Baker BI: Cell and molecular cell biology of melanin-concentrating hormone. *INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 213*. 233-277 (2002).
- Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, Wolff K, Pehamberger H, Jansen B: Bcl-x(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. *INT J CANCER* 99:29-34 (2002).
- Im S, Kim J, On WY, Kang WH: Increased expression of α -melanocyte-stimulating hormone in the lesional skin of melasma. *BRIT J DERMATOL* 146:165-167 (2002).
- Kim EM, Grace MK, O'Hare E, Billington CJ, Levine AS: Injection of α -MSH, but not β -endorphin, into the PVN decreases POMC gene expression in the ARC. *NEUROREPORT* 13:497-500 (2002).
- Klinger FG, DeFelici M: In vitro development of growing oocytes from fetal mouse oocytes: Stage-specific regulation by stem cell factor and granulosa cells. *DEVELOP BIOL* 244:85-95 (2002).

- Kramer BMR, Crujjsen PMJM, Ouwens DTWM, Coolen MW, Martens GJM, Roubos EW, Jenks BG: Evidence that brain-derived neurotrophic factor acts as an autocrine factor on pituitary melanotrope cells of *Xenopus laevis*. *ENDOCRINOLOGY* 143:1337-1345 (2002).
- Lázár G, Maderdrut JL, Merchenthaler I. Distribution of melanin-concentrating hormone-like immunoreactivity in the central nervous system of *Rana esculenta*. *BRAIN RES BULL* 57[3-4], 401-407. 2002.
- Massi D, Franchi A, Borgognoni L, Paglierani M, Reali UM, Santucci M: Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma - A quantitative morphologic analysis. *VIRCHOWS ARCHIV* 440:22-28 (2002).
- Mutulis F, Mutule H, Wikberg JES: N-alkylaminoacids and their derivatives interact with melanocortin receptors. *BIOORG MEDICINAL CHEM LETTER* 12:1039-1042 (2002).
- Oboki K, Morii E, Kataoka TR, Jippo T, Kitamura Y: Isoforms of mi transcription factor preferentially expressed in cultured mast cells of mice. *BIOCHEM BIOPHYS RES COMMUN* 290:1250-1254 (2002).
- Pavey S, Gabrielli B: α -melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. *CANCER RES* 62:875-880 (2002).
- Quto SS, Ng CE: Comparison of apoptotic, necrotic and clonogenic cell death and inhibition of cell growth following camptothecin and X-radiation treatment in a human melanoma and a human fibroblast cell line. *CANCER CHEMOTHER PHARMACOL* 49:167-175 (2002).
- Retsas S, Henry K, Mohammed MQ, MacRae K: Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. *EUR J CANCER* 38:511-516 (2002).
- Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA: Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptors. *CANCER RES* 62:1847-1853 (2002).
- Sato H, Nagashima Y, Chrousos GP, Ichihashi M, Funasaka Y: The expression of corticotropin-releasing hormone in melanoma. *PIGM CELL RES* 15:98-103 (2002).
- Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M: Insulin-like growth factor-I-induced migration of melanoma cells is mediated by interleukin-8 induction. *CELL GROWTH DIFFER* 13:87-93 (2002).
- Schiöth HB, Watanobe H: Melanocortins and reproduction. *BRAIN RES REV* 38:340-350 (2002).
- Slominski A, Semak I, Pisarchik A, Sweatman T, Szczesniowski A, Wortsman J: Conversion of L-tryptophan to serotonin and melatonin in human melanoma cells. *FEBS LETT* 511:102-106 (2002).
- Smalley KSM, Eisen TG: Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. *INT J CANCER* 98:514-522 (2002).
- Sounni NE, Baramova EN, Munaut C, Maquoi E, Frankenne F, Foidart JM, Noël A: Expression of membrane type 1 matrix metalloproteinase (MT1-MMP) in A2058 melanoma cells is associated with MMP-2 activation and increased tumor growth and vascularization. *INT J CANCER* 98:23-28 (2002).
- Straume O, Akslen LA: Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression. *AMER J PATHOL* 160:1009-1019 (2002).
- Voigtländer C, Rand A, Liu SL, Wilson TJ, Pittelkow MR, Getz MJ, Kelm RJ: Suppression of tissue factor expression, cofactor activity, and metastatic potential of murine melanoma cells by the N-terminal domain of adenovirus E1A 12S protein. *J CELL BIOCHEM* 85:54-71 (2002).
- Wu XFS, Rao K, Zhang H, Wang F, Sellers JR, Matesic LE, Copeland NG, Jenkins NA, Hammer JA: Identification of an organelle receptor for myosin-Va. *NAT CELL BIOL* 4:271-278 (2002).
- Youl P, Aitken J, Hayward N, Hogg D, Liu L, Lassam N, Martin N, Green A: Melanoma in adolescents: A case-control study of risk factors in Queensland, Australia. *INT J CANCER* 98:92-98 (2002).
- Yu C, Chen JCT, Apuzzo MLJ, O'Day S, Giannotta SL, Weber JS, Petrovich Z: Metastatic melanoma to the brain: Prognostic factors after gamma knife radiosurgery. *INT J RADIAT ONCOL BIOL PHYS* 52:1277-1287 (2002).
- Yu JL, Rak JW, Klement G, Kerbel RS: Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. *CANCER RES* 62:1838-1846 (2002).
- Zettersten E, Sagebiel RW, Miller JR, Tallapureddy S, Leong SPL, Kashani-Sabet M: Prognostic factors in patients with thick cutaneous melanoma (> 4 mm). *CANCER* 94:1049-1056 (2002).

DEVELOPMENTAL BIOLOGY

- Barber TD, Barber MC, Tomescu O, Barr FG, Ruben S, Friedman TB: Identification of target genes regulated by PAX3 and PAX3-FKHR in embryogenesis and alveolar rhabdomyosarcoma. *GENOMICS* 79:278-284 (2002).
- Bronner-Fraser M. Molecular analysis of neural crest formation. *J PHYSIOLOGY PARIS* 96[1-2], 3-8. 2002.
- Gefrides LA, Bennett GD, Fennell RH. Effects of folate supplementation on the risk of spontaneous and induced neural tube defects in splotch mice. *TERATOLOGY* 65[2], 63-69. 2002.

- Kamaraju AK, Bertolotto C, Chebath J, Revell M: Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling. *J BIOL CHEM* 277:15132-15141 (2002).
- Köklü S, Ertugrul D, Onat AM, Karakus S, Haznedaroglu IC, Büyükasik Y, Sayinalp N, Özcebe O, Dündar SV: Piebaldism associated with congenital dyserythropoietic anemia type II (HEMPAS). *AMER J HEMATOL* 69:210-213 (2002).
- Kwang SJ, Brugger SM, Lazik A, Merrill AE, Wu LY, Liu YH, Ishii M, Sangiorgi FO, Rauchman M, Sucov HM, Maas RL, Maxson RE: Msx2 is an immediate downstream effector of Pax3 in the development of the murine cardiac neural crest. *DEVELOPMENT* 129:527-538 (2002).
- Mayanil CSK, George D, Freilich L, Miljan EJ, Mania-Farnell B, McLone DG, Bremer EG: Microarray analysis detects novel Pax3 downstream target genes. *J BIOL CHEM* 276:49299-49309 (2001).
- Palumbo C, vanRoozendaal K, Gillis AJ, vanGurp RH, deMunnik H, Oosterhuis JW, vanZoelen EJ, Looijenga LH: Expression of the PDGF α -receptor 1.5 kb transcript, OCT-4, and c-KIT in human normal and malignant tissues. Implications for the early diagnosis of testicular germ cell tumours for our understanding of regulatory mechanisms. *J PATHOL* 196:467-477 (2002).
- Selicorni A, Gueneri S, Ratti A, Pizzuti A. Cytogenetic mapping of a novel locus for type II Waardenburg syndrome. *HUM GENET* 110[1], 64-67. 2002.
- Suzuki T, Li W, Zhang Q, Karim A, Novak EK, Sviderskaya EV et al. Hermansky-Pudlak syndrome is caused by mutations in HPS4, the human homolog of the mouse light-ear gene. *NAT GENET* 30[3], 321-324. 2002.
- Terry RB, Bailey E, Lear T, Cothran EG: Rejection of MITF and MGF as the genes responsible for appaloosa coat colour patterns in horses. *ANIM GENET* 33:82-84 (2002).
- Verheij JBG, Kunze J, Osinga J, vanEssen AJ, Hofstra RMW: ABCD syndrome is caused by a homozygous mutation in the EDNRB gene. *AMER J MED GENET* 108:223-225 (2002).
- Wiggin O, Fadel MP, Hamel PA: Pax3 induces cell aggregation and regulates phenotypic mesenchymal-epithelial interconversion. *J CELL SCI* 115:517-529 (2002).
- Wiggin O, Hamel PA: Pax3 regulates morphogenetic cell behavior in vitro coincident with activation of a PCP/non-canonical Wnt-signaling cascade. *J CELL SCI* 115:531-541 (2002).
- Zhang Q, Li W, Novak EK, Karim A, Mishra VS, Kingsmore SF et al. The gene for the muted (mu) mouse, a model for Hermansky-Pudlak syndrome, defines a novel protein which regulates vesicle trafficking. *HUM MOL GENET* 11[6], 697-706. 2002.

DIFFERENTIATION

- Cabanes J, Chazarra S, García-Carmona F: Tyrosinase kinetics: A semi-quantitative model of the mechanism of oxidation of monohydric and dihydric phenolic substrates - Reply. *J THEOR BIOL* 214:321-325 (2002).
- Camacho-Hübner A, Richard C, Beermann F: Genomic structure and evolutionary conservation of the tyrosinase gene family from Fugu. *GENE* 285:59-68 (2002).
- Challen MP, Zhang CJ, Elliott TJ: Agaricus bisporus and Coprinus bilanatus TRP2 genes are tri-functional with conserved intron and domain organisations. *FEMS MICROBIOL LETT* 208:269-274 (2002).
- Chen TH, Vazquez-Duhalt R, Wu CF, Bentley WE, Payne GF: Combinatorial screening for enzyme-mediated coupling. Tyrosinase-catalyzed coupling to create protein-chitosan conjugates. *BIOMACROMOLECULES* 2[2], 456-462. 2001.
- Fenoll LG, Rodríguez-López JN, García-Molina F, García-Cánovas F, Tudela J: Michaelis constants of mushroom tyrosinase with respect to oxygen in the presence of monophenols and diphenols. *INT J BIOCHEM CELL BIOL* 34:332-336 (2002).
- Freire RS, Thongngamdee S, Durán N, Wang J, Kubota LT. Mixed enzyme (laccase/tyrosinase)-based remote electrochemical biosensor for monitoring phenolic compounds. *ANALYST* 127[2], 258-261. 2002.
- Granter SR, Weilbaecher KN, Quigley C, Fisher DE: Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma. *APPL IMMUNOHISTOCHEM MOL MORP* 10:47-51 (2002).
- Gukasyan GS: Study of the kinetics of oxidation of monophenols by tyrosinase. The effect of reducers. *BIOCHEMISTRY ENGL TR* 67:277-280 (2002).
- Halaban R, Patton RS, Cheng E, Svedine S, Trombetta ES, Wahl ML, Ariyan S, Hebert DN: Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway. *J BIOL CHEM* 277:14821-14828 (2002).
- Harris RBS, Mitchell TD, Mynatt RL: Leptin responsiveness in mice that ectopically express agouti protein. *PHYSIOL BEHAV* 75:159-167 (2002).
- Hochberg M, Lotem M, Gimon Z, Shiloni E, Enk CD: Expression of tyrosinase, MIA and MART-1 in sentinel lymph nodes of patients with malignant melanoma. *BRIT J DERMATOL* 146:244-249 (2002).
- Kitamura Y, Morii E, Jippo T, Ito A: Regulation of mast cell phenotype by MITF. *INT ARCH ALLERGY IMMUNOL* 127:106-109 (2002).
- Lee HS: Tyrosinase inhibitors of Pulsatilla cernua root-derived materials. *J AGR FOOD CHEM* 50:1400-1403 (2002).

- López-Serrano D, Sanchez-Amat A, Solano F: Cloning and molecular characterization of a SDS-activated tyrosinase from *Marinomonas mediterranea*. *PIGM CELL RES* 15:104-111 (2002).
- Mansky KC, Sulzbacher S, Purdom G, Nelsen L, Hume DA, Rehli M, Ostrowski MC: The microphthalmia transcription factor and the related helix-loop-helix zipper factors TFE-3 and TFE-C collaborate to activate the tartrate-resistant acid phosphatase promoter. *J LEUKOCYTE BIOL* 71:304-310 (2002).
- Mansky KC, Marfatia K, Purdom GH, Luchin A, Hume DA, Ostrowski MC: The microphthalmia transcription factor (MITF) contains two N-terminal domains required for transactivation of osteoclast target promoters and rescue of mi mutant osteoclasts. *J LEUKOCYTE BIOL* 71:295-303 (2002).
- Mansky KC, Sankar U, Han JH, Ostrowski MC: Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF- κ B ligand signaling. *J BIOL CHEM* 277:11077-11083 (2002).
- Max N, Wolf K, Thiel E, Keilholz U: Quantitative nested real-time RT-PCR specific for tyrosinase transcripts to quantitate minimal residual disease. *CLIN CHIM ACTA* 317:39-46 (2002).
- Meyer CH, Lapolice DJ, Freedman SF: Foveal hypoplasia in oculocutaneous albinism demonstrated by optical coherence tomography. *AMER J OPHTHALMOL* 133:409-410 (2002).
- Miltenberger RJ, Wakamatsu K, Ito S, Woychik RP, Russell LB, Michaud EJ: Molecular and phenotypic analysis of 25 recessive, homozygous-viable alleles at the mouse agouti locus. *GENETICS* 160:659-674 (2002).
- Mitchell MS, Darrah D, Yeung D, Halpern S, Wallace A, Voland J, Jones V, Kan-Mitchell J: Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. *J CLIN ONCOL* 20:1075-1086 (2002).
- Morii E, Oboki K, Kataoka TR, Igarashi K, Kitamura Y: Interaction and cooperation of mi transcription factor (MITF) and myc-associated zinc-finger protein-related factor (MAZR) for transcription of mouse mast cell protease 6 gene. *J BIOL CHEM* 277:8566-8571 (2002).
- Piao LZ, Park HR, Park YK, Lee SK, Park JH, Park MK: Mushroom tyrosinase inhibition activity of some chromones. *CHEM PHARM BULL TOKYO* 50:309-311 (2002).
- Riley PA: Tyrosinase kinetics: A semi-quantitative model of the mechanism of oxidation of monohydric and dihydric phenolic substrates - Response. *J THEOR BIOL* 214:327-328 (2002).
- Sekyere E, Food MR, Richardson DR: A second melanotransferrin gene (Mtf2) and a novel protein isoform: explanation for the membrane-bound and soluble forms of melanotransferrin? *FEBS LETT* 512[1-3], 350-352. 2002.
- Selzer E, Wacheck V, Lucas T, Heere-Ress E, Wu M, Weilbaecher KN, Schlegel W, Valent P, Wrba F, Pehamberger H, Fisher D, Jansen B: The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. *CANCER RES* 62:2098-2103 (2002).
- Shi YL, Benzie IFF, Buswell JA: Role of tyrosinase in the genoprotective effect of the edible mushroom, *Agaricus bisporus*. *LIFE SCI* 70:1595-1608 (2002).
- Steingrimsson E, Tessarollo L, Pathak B, Hou L, Arnheiter H, Copeland NG, Jenkins NA: Mitf and Tfe3, two members of the Mitf-Tfe family of bHLH-Zip transcription factors, have important but functionally redundant roles in osteoclast development. *PROC NAT ACAD SCI USA* 99:4477-4482 (2002).
- Stowers L, Holy TE, Meister M, Dulac C, Koentges G: Loss of sex discrimination and male-male aggression in mice deficient for TRP2. *SCIENCE* 295:1493-1500 (2002).
- Takeda K, Yasumoto K, Kawaguchi N, Udono T, Watanabe K, Saito H, Takahashi K, Noda M, Shibahara S: Mitf-D, a newly identified isoform, expressed in the retinal pigment epithelium and monocyte-lineage cells affected by Mitf mutations. *BBA GENE STRUCT EXPRESS* 1574:15-23 (2002).

MISCELLANEOUS

- Brochez L, Verhaeghe E, Grosshans E, Haneke E, Piérard G, Rutter D, Naeyaert JM: Inter-observer variation in the histopathological diagnosis of clinically suspicious pigmented skin lesions. *J PATHOL* 196:459-466 (2002).
- Chang B, Hawes NL, Hurd RE, Davisson MT, Nusinowitz S, Heckenlively JR: Retinal degeneration mutants in the mouse. *VISION RES* 42:517-525 (2002).
- Hattar S, Liao HW, Takao M, Berson DM, Yau KW: Melanopsin-containing retinal ganglion cells: Architecture, projections, and intrinsic photosensitivity. *SCIENCE* 295:1065-1070 (2002).
- Kakinuma H, Kobayashi M: Eccrine poroma: another cause of a pigmented scalp nodule. *BRIT J DERMATOL* 146:523 (2002).
- Matschke J, Tsokos M, Spermhake J: Further comment on abnormally pigmented organs presenting at autopsy. *ARCH PATHOL LAB MED* 126:400 (2002).
- Moncrieff M, Cotton S, Claridge E, Hall P: Spectrophotometric intracutaneous analysis: a new technique for imaging pigmented skin lesions. *BRIT J DERMATOL* 146:448-457 (2002).